A	uthors	Publication title	Date Journal	Funding acknowledgement	Competing Interests	If relevant: clinical trial ID	Comments	Date of data extraction
				Trais Partnership (EDCTP) and was performed by the Malaria Nedored Vaciones Consortium (MVVC), a four and a half year integrated project funded by the European and Developing and Service of the half of the project				
A	folabi MO	Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants Long-term thermostabilization of live	Official journal of the American 2016 Society of Gene & Cell Therapy	Council. Cofunding was also provided by the Swedish International Development Cooperation Agency (Sdal) and Irish Aid. This research was supported by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and MC_UP_A900/1122		NCT01373879, NCT01450293, NCT01635647. PACTR201204000362870 PACTR201401000363170, PACTR201208000404131	N/A	08/12/2020
А	Icock R	poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass ChAdOx1 and MVA based vaccine	2010 Elselvier - Vaccine	No funding disclosure found	Conflict of interest: SCG is a co-founder of, consultant to and shareholder in Vac-ditech plc which is developing vectored influenza and MERSvaccines.	N/A	No funding disclosure found	16/12/20
	lharbi NK	candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice	2017 Vaccine	No funding statement found	SCG is a co-founder of, consultant to and shareholder in Vaccitech plc which is developing vectored influenza and MERS vaccines.	N/A	N/A	21/12/2020
А	lharbi NK	Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels Evaluation of Plasmodium vivax Cell-	2019 Nature	This study is funded by KAIMRC, project RC16/093 granted to the PI: Naif Khalaf Alharb; in addition, animals, research farm, and animal logistics were financially supported by MEWA, Saudi Arabia. SCG is a Jenner Investigator and supported the manufacturing of the vaccine batch.	SCG is a co-founder of and consultant to Vaccitech, a spin-out company from the University of Oxford which has commercial rights to ChAdOx1 MERS. ChAdOx1 MERS vaccine is registered as an IP, number: WO 2018/215766. The remaining authors declare no potential conflict of interest.	N/A	N/A	18/12/20
А	lves E	Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine Clinical assessment of a novel recombinant simian adenovirus	2017 Clinical and Vaccine Immunology	The work was funded by a Wellcome Trust Career Development Fellowship award (grant number 097395/2/11/2) to A.RS.	N/A	N/A	N/A	08/12/2020
	ntrobus RD sthagiri Arunkumar G	ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens	2014 Molecular Therapy	The study was funded by grants from the UK MRC, the NIHR through the Oxford Biomedical Research Centre, and the Oxford Martin school.	The Icahn School of Medicine at Mount Sinai has filed patentapplications regarding influenza virus	NCT01623518	N/A	08/12/2020
		Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice	2019 Elselvier Vaccine	The study was fundedby an MRC Biomedical Catalyst DPS. DCS award (MR/N006372/1). In addition, this study was partially funded by the NIAID Centers of Excellence for Influenza Research and Surveillance contract(EEIRS, HHSN27220140000BC). And rian I loannou was supportedby an NIAID 132 Virus-Host Interactions training grant(\$132A007647-17). The work was founded by a Wellcome Trust Career Development Fellowship award(grant	vaccines with FlorianKrammer being an inventor. Sarah Gilbert is an inventor on patentscovering ChadOx1 and MVA-NP+M1, filed and owned by theUniversity of Oxford, and is a co-founder of and consultant toWaccitech, a University of Oxford spin-out company which is undertaking advanced dinical development of viral vectored influenza vaccines.	N/A	N/A	18/12/20
		Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP		097395/Z/11/Z) to A.RS., who is also a lenner Investigator and an Oxford MartinFellow and is supported by MRC-DPFS (grant MR/N019008/1). A.M.S. was funded byEVMalaR's program fundin (FP7/2007-2013) under grant agreement number 242095. E.A.was funded by CAPES from Science without Border program. A.V.S.H. is supported by aWellcome Trust grant (number 095540/Z/11/Z)				
А	tcheson E	Viral Vectors Novel adenovirus-based vaccines induce	2018 Infection and Immunity	and is a Jenner Investigator and an OxfordMartin Fellow. European Union (Framework VI;HEPACIVAC); Medical Research Council (UK); Wellcome Trust; Oxford NIHR Biomedical Research.Centre; James Martin School for 21st Century, Oxford; Wellcome	N/A S. Colloca, A.F., R.C., and A.N. are named inventors on patent applications covering HCV-vectored vaccines and chimpanzee ad-enovirus vectors [WO 2006133911 (A3) hepatitis Cvirus nucleic acid vaccine, WO 2005071093 (A3)chimpanzee adenovirus vaccine carriers, WO 2005071093 (A3)chimpanzee adenovirus vaccine carriers, WO 2005071093 (A3)chimpanzee adenovirus vaccine (A3)chimpa	N/A	N/A	10/12/2020
	arnes E arnes E	broad and sustained T cell responses to HCV in man ChAdOx1-HBV therapeutic vaccine: Phase 1 study results in healthy	2012 Science Transitional Medicine N/A - only on clinicaltrials.gov	Trust Clinical Research Facility, Birmingham; National Institute for Health and Research Liver Biomedical Research Unit, Birmingham; and NIH grant 1U19AI082630-01.	from Okairos are employees of and/or shareholders in Okairos. The other authors declare that they have no competing interests.	NCT01070407, 2007-004259-12	N/A	10/12/2020
		volunteers and patients with chronic hepatitis B Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing	n/a - only on clinicaltrials.gov (https://clinicaltrials.gov/ct2/show/ 2020 CT04297917)	N/A The work was funded by a Welkome Trust Career Development Fel-lowship award, grant number 097395, to A.RS. A.RS. and A.V.S.H. arelenner Investigators and Oxford Martin School Fellows.	N/A	NCT04297917	Study still recruiting	18/12/20
В	auza K	volunteers and patients with chronic hepatitis B Efficacy of a Plasmodium vivax malaria vaccine using ChAdG3 and modified vaccinia Ankara expressing thrombospon din-related anonymous protein as assessed with transgenic	(https://clinicaltrials.gov/ct2/show/	N/A The work was funded by a Wellcome Trust Career Development Fel-lowship award, grant number	N/A The authors have read the journal's policy and have the following conflicts: AVSH, AAP, and HM are named inventors in a patient filing elated to MVASSA and are shareholders in a joint venture, OETC.	N/A	Study still recruiting	18/12/20 10/12/2020
	auza K etts G	volunteers and patients with chronic hepatitis B Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic	(https://dinicaltrials.gov/ct2/show/ 2020 CT04297917)	N/A The work was funded by a Welkome Trust Career Development Fel-lowship award, grant number 077935, to A.R.S., A.R.S. and A.V.S.H. aretienner investigators and Oxford Martin School Fellows. E.Y.J. and T.M. are funded by the Medical Research Council and Cancer Research Undedingsion. Welkome Trust Sanger Institute was funded by Welkome Trust grant number WT098051. Funding was provided by NEWTBVAC (EC FPT). HM is a Welkome Trust Senior Research Fellow (www.welkome.ac.uk) VT0709432MA). HM, AH and AR-Sare Jenner Institute Investigators. AR-S is Welkome Trust Grant Development ARIO Senior Research Fellow (www.welkome.ac.uk) vT0709432MA). HM, AH and AR-Sare Jenner Institute Investigators. AR-S is Welkome Trust Grant Plancher Medical Research Connocil (MRC). They Avenue. ac.uk) grant Plancher Marchael Research Connocil (MRC). They Avenue. ac.uk) grant Plancher Marchael Research Connocil (MRC) They Avenue. ac.uk) grant Plancher Marchael Research Connocil (MRC). They Avenue. ac.uk) grant Plancher Marchael Research Connocil (MRC). They Avenue. ac.uk) grant Plancher Marchael Research Connocil (MRC). They Avenue. ac.uk) grant Plancher Marchael Research Connocil (MRC). They Avenue. ac.uk) grant Plancher Marchael Research Connocil (MRC). They Avenue. ac.uk) grant Plancher Marchael Research Connocil (MRC). They Avenue. ac.uk) grant Plancher Marchael Research Connocil (MRC). They Avenue. ac.uk) grant Plancher Marchael Research Connocil (MRC). They Avenue. ac.uk) grant Plancher Marchael Research Connocil (MRC). They Avenue. ac.uk) grant Plancher Marchael Plancher Ma	N/A The authors have read the journal's policy and have the following conflicts: AVSH, AAP, and IHM are named inventors in a pattent filing elated to MYABSA and are shareholders in a joint venture. OFTC, formed for the future development of this vaccine. AVSH and rM are named as commention organization there are also other inventions organized with the control of	N/A	,	-,-,-
		volunteers and patients with chronic hepatitis B Efficacy of a Plasmodium vivax malaria section using ChAGS and modified vaccinia Ankara expressing thrombospondiar-related anonymous protein as assessed with transgenic Plasmodium bergheip parasites (Plasmodium bergheip parasites) Optimising immunogenicity with viral vectors: mixing MVA and HAGV-5 expressing the mycobacterial antigen	(https://dinkaltrials.gov/ct2/show/ 2020 CT04297917) 2014 Infection and Immunity	The work was funded by a Welkome Trust Career Development Fel-lowship award, grant number 097939, to A.R.S., A.RS. and A.V.S.H. arelenner investigators and Oxford Martin School Fellows. E.Y.J. and T.M. are funded by the Medical Research Council and Cancer Research United Grigorium Oxfor & the Welkome Trust Samper Institute was funded by Welkome Trust grant number WT098051. Funding was provided by NEWTBVAC (EC.FP7). HM is a Welkome Trust Senior Research Fellow (www.welkome.ac.uk; WT079843MA). HM, AH and AR-Sare Jenner Institute Investigators. AR-S is Welkome Trust Career Development Fellow (097395). This work was supported by the U.K. Medical Research Council (MRC, http://www.mrc.ac.uk) Igrant number (1970-1970). It is the More Control of the C	N/A The authors have read the journal's policy and have the following conflicts: AVSH, AAP, and IHM are named inventors in a pattent filing elated to MYABSA and are shareholders in a joint venture. OFTC, formed for the future development of this vaccine. AVSH and rM are named as commention organization there are also other inventions organized with the control of	N/A	,	10/12/2020
В		volunteers and patients with chronic hepatitis B Efficacy of a Plasmodium vivax malaria section using ChAGS and modified vaccinia Ankara expressing thrombospondiar-related anonymous protein as assessed with transgenic Plasmodium bergheip parasites (Plasmodium bergheip parasites) Optimising immunogenicity with viral vectors: mixing MVA and HAGV-5 expressing the mycobacterial antigen	(https://dinkaltrials.gov/ct2/show/ 2020 CT04297917) 2014 Infection and Immunity	N/A The work was funded by a Wellcome Trust Career Development Fel-lowship award, grant number 097395, to A.S. S. A.S. S. and A.V.S.H. are immer investigators and Oxford Martin School Fellows. Work at the Wellcome Trust Sanger Institute was funded by Wellcome Trust grant number VTOR8051. Funding was provided by NEWTBMC (ES. FP), IMN is a Wellcome Trust Senior Research Fellow (www.wellcome ac.uk; VTTO78051M.) IMN, AH and AB-Sare Jenner Institute Investigators. AMS is Wellcome Trust Career Development Fellow (07785). This work was supported by the EWTBMC (ES. FP), IMN is a Wellcome Trust Senior Research Fellow (18 Wellcome Trust Senior Research	N/A The authors have read the journal's policy and have the following conflicts: AVSH, AAP, and IHM are named inventors in a pattent filing elated to MYABSA and are shareholders in a joint venture. OFTC, formed for the future development of this vaccine. AVSH and rM are named as commention organization there are also other inventions organized with the control of	n/a ·	,	10/12/2020
В	etts G	volunteers and patients with chronic hepatitis B Efficacy of a Plasmodium vivax malaria vaccine using CnA63 and modified vaccine a Anhara expressing thrombopsondin-related amonymous protein an assessed with related amonymous proteins as susceed with related amonymous proteins as susceed with related amonymous proteins assessed with related amonymous vectors: making MVM and MAGV-5 expressing the mytoobacterial antigen Ag65A in a single injection Assessment of humoral immune responses to blood-stage malaria antigens following ChA653-MVA immunication, controlled human malaria infection and natural exposure Transgene optimization, immunogenicina and in vitro efficacy of viral vectored	(https://dinkaltrials.gov/ct2/show/ 2020 CT04297917) 2014 Infection and Immunity 2012 Plos One	N/A The work was funded by a Wellcome Trust Career Development Fellowship award, grant number 97:395, to AAS. A.R. 5. and A.V.S.H. are immer investigators and Oxford Martin School Fellows. EXP 207:395, to AAS. A.R. 5. and A.V.S.H. are immer investigators and Oxford Martin School Fellows. Work at the Wellcome Trust Sanger Institute was funded by Wellcome Trust grant number WT088051. Work at the Wellcome Trust Sanger Institute was funded by Wellcome Trust grant number WT088051. Funding was provided by NEWTBVAC (EC FP). HM is a Wellcome Trust Senior Research Fellow (www.wellcome ac.uk; WT0780541M, MA AH and AR-Sare Jenner Institute Investigators. AR-S is Wellcome Trust Career Development Fellow (073785). This work was supported by the WTWDAC (Exception Hardward Council (MRC, http://www.mc.ac.uk) (grant number G0700735); the EMVDA (European Malaria/Vaccine Development Association; intt.//www.eventor.ac.g.) a European Commission FP6-inded consortium (EVRF-C72007-027500); http://www.mc.ac.uk) (grant number G0700735); the EMVDA (European Mariaria/Vaccine Development Association; intt.//www.eventor.ac.g.) a European Community Seventh Framework Fraggrammer (P77007-2013) (Grant agreement No. 24095); The GIA work was supported by the PATH Maharia Vaccine Initiative (Intley/News.mahariavaccine.org) and Infectious Diseases (http://www.niadi.nin.gov). 519th holds a Wellcome Trust Research Training Fellowship (079780/21172), AVS and Son are Jenner Investigators (http://www.niadi.raning.org.) (Eccolor) (Economistication) (Economistication	N/A The authors have read the journal's policy and have the following conflicts: AVSH AAP and HM are named so reventors in a patent filingeleted to MAVSSA and are observed in a joint venture, OETC formed for the flux development of the vaccies. AVSH and M are named as considered in the vaccies. AVSH and M are named as considered interest value of an any site refer withithe authors' adherence to the journal's policies on sharing data and materials. SCAC, KAC, AVSH and SID are named inventors on patent applications covering malaria vaccines and immunitation regimes (Adenoviralvectors excoding a pathogen or tumour antigen, WO/2008/12811, Viral vector immunogenic compositions, Galfary 3.3. This does not alter the authors' adherence to PLoS ONE policies on sharing data and materials. SID, SCG and AVSH are named inventors on patent applications covering malaria vaccines and immunitation regimes. (Adenoviralvectors excoding a pathogen or tumour antigen, WO/2008/12811, Viral vector immunogenic compositions, Galfary 3.3. This does not alter the authors' adherence to PLoS ONE policies on sharing data and materials.	N/A N/A NCT01095055, NCT01003314,	N/A	10/12/2020
В	etts G	volunteers and patients with chronic hepatitis B Efficacy of a Plasmodium vivax malaria vaccine using Ch4653 and modified vaccine a Anhara expressing vaccine a Anhara expressing vaccine a Anhara expressing vaccine a Anhara expressing vaccine as well as a vaccine size of the Anhara expressing the vaccine size of the Anhara expressing the mylorabeterial sanger of the Anhara expressing the mylorabeterial sanger Agifica in a single injection. Assessment of humoral immune responses to blood-stage malaria anrigers following Ch4653-MYA immunification, controlled humoralism controlled humoralism indicated humoralism controlled humoralism indicated humoralism	(https://dinkaltrials.gov/ct2/show/ 2020 CT04297917) 2014 Infection and Immunity 2012 Plos One	The work was funded by a Wellcome Trust Career Development Fel-lowship award, grant number 077925, to A.R.S., A.R.S., and A.V.S.H. are inner investigators and Oxford Martin School Fellows. E.Y.J. and T.M. are funded by the Medical Research Council and Cancer Research Undedingdom. Wellcome Trust Sanger Institute was funded by Wellcome Trust grant number WT098051. Funding was provided by NEWTBVAC (EC FPT). HM is a Wellcome Trust Senior Research Fellow (Iwww.wellcome.ac.uk). WT079843MA). HM, AH and AR-Sare Jenner Institute Investigators. AR-S is Wellcome Trust Gareer Development Fellow (Iwww.wellcome.ac.uk). WT079843MA). HM, AH and AR-Sare Jenner Institute Investigators. AR-S is Wellcome Trust Gareer Development Fellow (1972807). Wellcome Trust Gareer Development Fellow (1972807). Wellcome Trust Gareer Development Fellow (1972807). Wellcome Trust Gareer Development Community Martin (1972). Wellcome Trust Gareer Development Community Seventh Institute of Intelligent Community Seventh Framework Programme (1977/2007-2013) (Icaran Tagreement No. 24059). The GA work was supported by the PST IMMAIN (Italy John Washer). Wellcome Trust Research Training Fellowship (1979/2007) (1712). And by EMINIAI (Italy John Washer). Sea Noth Leadership Fellow (16100527) and Lister Institute Research Prize Fellow (16100527) and Lister Institute Re	N/A The authors have read the journal's polity and have the following conflicts: AVSH, AAP, and HM are named inventors in a patent filingestated to MVASSA and are shareholders in a joint venture, OETC, formed for the future development of the vacione. AVSH and Mar ea named as commented to the vacione and the vacione. AVSH and Mar ea named as commented inventors are shareholders. There are no other conflicts of interest. These conflicts of interest. These conflicts of interest will not in any with terfere withthe authors' adherence to the journal's policies on sharing data and materials. SCGC, IACC, AVSH and SID are named inventors on patent applications covering malaria vaccines and immunication regimes (Adenoviralvectors exoding a pathogen or furnour antigen, Vaccional Conflicts). This does not alter the author's adherence to PLoS ONE policies on sharing data and materials. SDD, SCG and AVSH are named inventors on patent applications covering malaria vaccines and immunication regimes. Authorsfrom Chairo's are employees of and/or shareholders in distinct and minimization regimes. Authorsfrom Chairo's are employees of and/or shareholders in the distinct of the properties of antique of the author's adherence to PLoS ONE policies on sharing data and materials.	N/A N/A NCT01095055, NCT01003314,	N/A	10/12/2020
8 8	etts G	volunteers and patients with chronic hepatitis B Efficacy of a Plasmodium vious malaria vaccine using Chi-doSa and modified vaccina shariar expressing vaccine using Chi-doSa and modified vaccina shariar expressing vaccine shariar expressing vaccine shariar expressing protein as assessed with transgenic Plasmodium berghei parasites Optimising immunogenicity with viral vectors: mining MVM and MAde-5 expression ground protein and assessed and protein and protein and assessment of humoral immunication, controlled human malaria infection and natural exposure Transgene optimization, immunogenichi and in vitro efficacy of viral vectored in vaccines expression to efficacy of viral vectored in vaccines expression to alless of vectored in vaccines expression to alless of vectored in vaccines expression to and in vitro efficacy of viral vectored in vaccines expression to alless of vectored vaccines expression to all vectored vaccines expression to alless of vectored vaccines expression to alless of vectored vaccines expression to alless of vectored vaccines expression to all vectored vaccines expression to alless of vectored vaccines expression to alless of vectored vaccines expression to alless of vectored vaccines expression to all vectored vaccines expression to all vaccines	(https://dinkaltrials.gov/ct2/show/ 2020 CT04297917) 2014 Infection and Immunity 2012 Plos One	The work was funded by a Wellcome Trust Career Development Fellowship award, grant number 077925, to A.R.S., A.R.S., and A.V.S.H. are lenner investigators and Oxford Martin School Fellows. E.Y.J. and T.M. are funded by the Medical Research Council and Cancer Research Uniteditingtion. Which are funded by the Medical Research Council and Cancer Research Uniteditingtion. Which are the Career of	N/A The authors have read the journal's policy and have the following conflicts: AVSH AAP and HM are most do reverted in a placet litingleished to MVASSA and are shareholders in a joint venture, OFTC, formed for the future development of the vaccine. AVSH and M are named accommendation related to beterologous prime-boost immunization. There are no other conflicts of interest. These conflicts of interest will not in any systemic resultance of the placetimes of the placetimes will not any systemic resultance and the placetimes of	N/A N/A NCT01095055, NCT01003314,	N/A	10/12/2020 10/12/2020 10/12/2020
8 8	etts G Iswas 5 Iswas 5	volunteers and patients with chronic hepatitis B Efficacy of a Plasmodium vious malaria vaccine using CNA653 and modified vaccine a Anhara expressing thrombopsondin-related amonymous control of the properties of the proposal control of the proposal control of the proposal control of the properties of the proposal control o	(https://dinkaltrisks.gov/ct2/show/ 2020 CT04297917) 2014 Infection and Immunity 2012 Plos One 2014 Plos One 2011 Plos One	N/A The work was funded by a Wellcome Trust Career Development Fellowship award, grant number 97:395, to AAS. A.R. 5. and A.V.S.H. are immer investigators and Oxford Markin School Fellows. EXP 3935, to AAS. A.R. 5. and A.V.S.H. are immer investigators and Oxford Markin School Fellows. Work at the Wellcome Trust Sanger Institute was funded by Wellcome Trust grant number VTOR8051. Work at the Wellcome Trust Sanger Institute was funded by Wellcome Trust grant number VTOR8051. Funding was provided by NEWTBVAC (EC FP). HM is a Wellcome Trust Senior Research Fellow (www.wellcome ac.uk; VTOT78054M). MM, AH and AR-Sare Jenner Institute Investigators. AR-S is Wellcome Trust Career Development Fellow (073785). This work was supported by the WINDA (European Malaria/Accene Development Association; Instituty/www.emca.ec.uk) Igrant number GOT00705; the EMVDA (European Institute) (MRC, http://www.mc.ac.uk) Igrant number GOT00705; the EMVDA (European Institute) (MRC, http://www.mc.ac.uk) Igrant number GOT00705; the EMVDA (European Institute) (MRC, http://www.malariavccine.org) and infectious Diseases that phylometry and the Institute of Jackery and Institute of Jackery and Institute of Jackery and Institute of Jackery and Institute Oxida (MRC, http://www.malariavccine.org) and Institute of Jackery and Institute of Jackery and Institute Oxida (MRC, http://www.malariavccine.org) and Institute of Jackery and Institute of Jackery and Institute Oxida (MRC, http://www.malariavccine.org) and Institute Oxida (MRC, http://www.malariavccine.org) and Institute Oxida (MRC, http://www.malariavccine.org) and Institute of Jackery and Institute of Jackery and Institute Oxida (MRC, http://www.malariavccine.org) and Institute org. William (MRC, http://www.malariavccine.org) and Institute Oxida (MRC, http://www.malariavccine.org) and Institute Oxida (MRC,	N/A The authors have read the journal's policy and have the following conflicts: AVSH, AAP, and HM are named inventors in a patent filingrelated to MVASSA and are observed in a joint venture, DETC, formed for the flux development of the vaccine. AVSH and M are named as considered in the vaccine. AVSH and M are named as considered in the vaccine. AVSH and M are named as considered in the vaccine. AVSH and was related as considered in the vaccine. AVSH and was related as considered in the vaccine avst and the vaccine avst and the vaccine avst and the vaccine and immunitation regimes. (Alexnoviralvectors encoding a pathogen or tumour antigen, MO/2008/2281; I'val vector immunogenic compositions, Gallos/1247; J). This does not after the authors' adherence to PLoS ONE policies on sharing data and materials. SID, SCG and AVSH are named inventors on patent applications covering malaria vaccines and immunitation regimes. Authors/from Okairo: a remployees of and/or shareholders in Okairo; which is developing vectored malaria vaccines. This does not after the authors' adherence to PLoS ONE policies on sharing data and materials. SID, SCG and AVSH are named inventors on patent applications covering malaria vectored vaccines and immunitation regimes. Authors/from Okairo: a remployees of and/or shareholders in melitare vaccines. This does not after the authors' adherence to all the PLOS Offer places on sharing data and materials. AND ALS Who was a shareholders in ReThera, which is developing vectored vaccines and immunitation regimes. Sclenno Colloca and Affecto Nicosia are employees of and/or shareholders in ReThera, which is developing vectored vaccines and immunitation and other diseases. ANJS H, is armed as an inventor or a spatent covering use of ChaldOrd. vectored vaccines and vectored vaccines and water of the vaccines and antivertion and advent distinguish to developing advectored vaccines and extended to complete a protection and Advent during the consist of vectored vaccines and advention the consist of the ve	N/A NCT01095655, NCT01003314, NCT01142765, NCT008890700 N/A NCT03364883, 2010-023824-26	n/a n/a	10/12/2020 10/12/2020 10/12/2020
B B B B B B	etts G Iswas 5 Iswas 5	volunteers and patients with chronic hepatitis B Efficacy of a Plasmodium vious malaria vaccine using Chi Addis and modified vaccina Anitra expressing vaccine using Chi Addis and modified vaccina Anitra expressing vaccine and vaccine and vaccine and vaccine anitrate vaccine simple parasites. Optimising immunogenicity with viral vectors: mixing MVM and MAdV2-vectors: mixing MVM and MAdV2-vectors: mixing MVM and MAdV2-vectors in the proposate of the parasites of the proposate of the parasites of the parasite of the parasites of the parasite of the paras	(https://dinkaltrials.gov/ct2/show/ 2020 CT04297917) 2014 Infection and Immunity 2012 Plos One 2014 Plos One 2014 Plos One	The work was funded by a Wellcome Trust Career Development Feliowship award, grant number 0779755, to A.R.S. A.R.S. and A.V.S.H. aretiement investigators and Oxford Martin School Fellows. Life 178755, to A.R.S. A.R.S. and A.V.S.H. aretiement investigators and Oxford Martin School Fellows. Life 178755, to A.R.S. A.R.S. and A.V.S.H. aretiement investigators and Oxford Martin School Fellows. Life 178755, and the Career of	N/A The authors have read the journal's policy and have the following conflicts: AVSH AAP and HM are most do revenue to a patent filippelated to MVASSA and are shareholders in a joint venture, OFTC, formed for the future development of the vaccine. AVSH and M are named as confined for the first evelopment of the vaccine. AVSH and M are named as considered in the conflicts of interest. These conflicts of interest have one and yet interfere withthe authors' adherence to the journal's policies on sharing data and materials. SSGC, MAC, AVSH and SSD are named inventors on patent applications covering malaria vaccines and immunitation regimes (Adenoviralvectors exocinging a pathogen or tumour antigen, WO/2008/22811; Varied vector immunopier compositions, GSIGAF41.3). This does not after the authors' adherence to PLoS ONE policies on sharing data and materials. SSO, SCG and AVSH are named inventors on patent applications covering malaria vaccines and immunitation regimes (Adenoviralvectors exocinging a pathogen or tumour antigen, WO/2008/22811; Varied vector immunopier compositions, GSIGAF41.3). This does not after the authors' adherence to PLoS ONE policies on sharing data and materials. SSO, SCG and AVSH are named inventors on patent applications covering malaria vaccines and immunitation regimes. Authors' from GRING's as employees of angle or starterobleters in Collario 3, which is developing techniques and malaria vaccines and immunitation collocies on sharing data and materials. Adrian Hill and Sarah Gilbert are named inventors on patent applications and patents relating too call the PLOS ONE policies on sharing data and materials. Adrian Hill and Sarah Gilbert are named inventors on patent applications and patents relating too call the PLOS ONE policies on sharing data and materials. AVIS H. Is named at an inventor on a patent covering use of ChAdGict -vectored vaccines for malaria vaccine vectors of consultant to, and shareholder in Vaccines pick which is developing ad-	N/A NCT01095005, NCT01003314, NCT01142785, NCT00880760	N/A N/A N/A N/A	10/12/2020 10/12/2020 10/12/2020 10/12/2020

В	owyer G	Activation-induced Markers Detect Vaccine-Specific CD4*T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials	2018 Vaccines	Trials Partnership, with additional funding from the NIHR Oxford Biomedical Research Centre. The Oxford clinical trial was supported by funding from an Enhancement Award to a Wellcomer Trust Strategic Award (to A. V.S. Hill as principal investigator) cofunded by the UK Medical Research Council, the UK Department for International Development, and the European and Developing	A.V.S.H. is a named inventor on patents relating to viral vectored vaccines. All other authors declares no conflicts of interest.	NCT02451891, 2015-000593-3	N/A	21/12/2020
В	owyer G	Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KIRG1+T Crells Towards a univestal vaccine for avian influenza; protective efficacy of modified Vaccine with surfa surfar and	2020 JEM	Countries ClinicalTrials Panneshlp, with additional funding from the Nationalinstitute for Health Research Oxford Biomedical Research Cert - ClassSom/Binkle Biologicals Sx supplied the ChAd3-E6D-Zvaccine and had the opportunity to review this manuscript. TheMVM-E8D-Z vaccine was biomanifactured for these trials bytemique flow under a contract from Oxford Universitywith funding from the same Enhancement Award. The Sene-galese trial was largely funded by a European Commission for 1-cion 2020 program award, EbolaVac (http://www.ebolavac.eu/, grant agreement no. 666085.	n/a	NCT02451891	N/A	18/12/20
В	oyd AC	Adenovirus vaccines expressing conserved influents antigens in chickens challenged with low pathogenic avian influenza virus Immunity, safety and protection of an Adenovirus 5 prime—Modified Vaccinia	2013 Elselvier - Vaccine	The Biotechnology and Biological Sciences Research Council and Wellcome Trust are gratefully acknowledged for their financial support.	N/A	N/A	N/A	16/12/20
В	ull TJ	virus Ankara boost subunit vaccine against Mycobacterium avium subspecies paratuberculosis infection in calves Immune responses against a liver-stage malaria antigen induced by simian	2014 Veterinary Research	This work was supported by Biotechnology and Biological Sciences Research.Council (BBSRC) grants 88/H0105556/1 and 88/H010718/1. Jayne Hope and/rene McGuinnes were supported by Institute Strategic Grant funding from the BBSRC	TJB is a minor shareholder in HAV Vaccines Ltd.	N/A	N/A	20/12/2020
C	apone S	adenoviral vector AdCh63 and MVA prime-boost immunisation in non- human primates 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer	2010 Elselvier - Vaccine	This work was supported by the Welkome Trust. AVSH is a Welkome Trust Principal Research Fellow. This work was supported by Oxford National Institutes for Health Research (NIHR) Biomedical Research Centre, UK (IR); the UK Medical Research Council CICG award (SS), the UK Welkome Trust Seriol (Irwest) galors / Sward (IAVSH) and the European Union's Seventh Framework Programme	N/A	N/A	N/A	16/12/20
C	appuccini F	immunotherapy Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in	2017 Oncotarget	under grant agreement No. 602705 ((FC, EP).	N/A	N/A	N/A	21/12/2020
C	appuccini F	early stage prostate cancer: a phase I clinical trial Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and	Journal for ImmunoTherapy of 2020 Cancer	The VAMCE clinical trial was supported by the European Union's Seventh Framework Programme under grant agreement no. 602705. This work was supported by Oxford National Institutes for Health Research (NIHR) Biomedical Research Centre LUK (I. Reddhenlo:) the UK Medical Research Council CGG award (S. Stribbling). the	AVSH is a co-founder of and shareholder in Vaccitech Ltd which has supported the Oxford prostate cancer vaccine programme.	NCT02390063	N/A	18/12/20
C	appuccini F	in combination with PD-1 mAb in a mouse model of prostate cancer Microneedle-mediated immunization of an adenovirus-based malaria vaccine	2016 Cancer Immunol Immunother	UK Wellcome Trust Senior Investigator's Award (A.V.S. Hill) and the European Union's Seventh Framework Programme under Grant Agreement No. 602705 (F. Cappuccini, E. Pollock)	N/A	N/A	N/A	21/12/2020
c	arey JB	enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route	2014 Scientific Reports	This work wassupported by Enterprise Ireland (Commercialisation Fund, CF1007/L17) and ScienceFoundstion Ireland (National Locess Programme 7 on and 170). AVSH and SID are Jennerinvestigators; and SID is a UK MRC Career Development Fellow [G1000527] and ListerInstitute Research Prite Fellow.	The authors declare no competing financial interests. AVSH and SID are named inventors on patient applications covering malaria vectored-vaccines and immunization regimes. JBC, AV, CDM, AVSH, ACM are named inventors on	N/A HCV vaccine phase 1 trial (HCV001) was registered with the European Clinica	N/A	16/12/20
		Vaccine vectors derived from a large collection of simian adenoviruses induce		This work was supported in part by Hepacivac (LSH 2005-1.2.4-2 project 037435)and the Wellcome		Trial database (EudracT number: 2007- 004259-12) and with the ClinicalTrials.gov database (ID: NCT01070407); malaria vaccine clinical trial (VAC043) was registered with the European Clinical Trial database (EudraCT number: 2010-023824-26) and		
c	olloca S	potent cellular immunity across multiple species Modification of Antigen Impacts on	2012 Science Transitional Medicine	Trust. A.V.S.H. was supported by a Wellcome Trust Principal Research Fel-lowship. E.B. was supported by Medical Research Council (UK).Author	N/A	with theClinicalTrials.gov database (ID: NCT01364883).	Clinical trials not this study but referenced studies	16/12/2020
c	olston JM	Memory Quality after Adenovirus Vaccination	2016 The Journal of Immunology	This work was supported by Wellcome Trust Grants 099897/Z/12/A and 091663MA.	N/A	N/A	N/A	20/12/2020
		Preventing spontaneous genetic		This work was supported by the European Vaccine Initiative, theOxford Martin School, the Gates Foundation through the Foundation NIH, The Wellcome Trust, and the NIHR Oxford BiomedicalResearch Centre. We are grateful to Dr. Alexandra J. Spencer, Jennerinstitute, University of Oxford, for assistance with immunology; toMr. Jake Matthews, Vector Core Facility, Jenner Institute, University Oxford, for assistance with Chade-Shr\$230, and to P. Nicola K. Green and Dr. Institute, University Oxford, for assistance with Chade-Shr\$230, and to P. Nicola K. Green and Dr.				
G	ottingham MG	rearrangements in the transgene cassettes of adenovirus vectors Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular	2012 Biotechnology and Bioengineering		Conflict of interest: Okairo's Srl and the University of Oxford hold intellectual propertyrelated to adenovirus vaccine vectors. SG and AVH are co-founders of Vaccitech, a company developingviral vectored vaccines including	N/A	N/A	16/12/20
C	oughlan L	vectors Long-Lasting Centural Immunity to Influenza Virus A in Healthy Adults A phase la study to assess the safety and immunogenicity of new malaria	2018 Elselvier	Research through theOxford Biomedical Research Centre (A91301 AdultVaccine) and the Wellcome	broadly cross-reactive influenta vac-cines. SS holds stock in Sanofflesteur which develops and markets in riluena vaccines. HG received a travel grant from Abbvie. The authors have read thejournal's policy and have the following conflicts: AVSH and SCG are named inventors on patentillings related to immunisation with vectored malariavaccines, specifically WOOSIQ1275R9. None of othese products have been commercialized. AM wasan	NCT01818362	N/A	18/12/20
d	e Barra E	vaccine candidates ChAd63 CS administered alone and with MVA CS	2014 Plos One	Training Fellowship (097940/Z/11/Z). The funders had no role in study design, data collection and analysis, decision topublish, or preparation of the manuscript.	not alterthese authors' adherence to all PLOS ONE policieson sharing data and materials, as detailed online inthe guide for authors.	NCT01450280	N/A	16/12/20
		The requirement for potent adjuvants to		S.C.d. C. a Ph.D. student supported by the European Malairal Vaccine DevelopmentAssociation, a European Commission Framework Programme -Funded constrating/fame1159-F-12007-037508]. This work was also partly supported by the Well-come Trust (Grant 084113/2/07/2), the National Institute for Health Research DrGrod Biomedical Research Centre, TRAMSVAC, a European Commission FrameworkProgramme 7-Invaded consortium Infrastructure grant, and grants to C.E.C. and V.S. Cfrom the Department of Biotechnology, Government of India, and European Vaccinentiatives. C.E. E. supported by 7 Tals Inmovation Fellowship from the Department				
d	e Cassan SC	enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus Differential immunogenicity between HAdV-5 and chimpanzee	2011 The Journal of Immunology	valcorientatives. C.C.L. Suppleted by a list all minoration revolving in this me Department of Bibliothoniog, Government of India. A.V.S.H. was supported by a Velicioner TrustPrincipal Research Fellowship. S.C.G., A.V.S.H., and S.J.O. are Jenner Investigators. S.J.D. is a Medical Research Council Career Development Fellow (Grant G1000527).	Disclosures: S.C.d.C., E.K.F., A.D.D., A.M., S.C.G., A.V.S.H., and S.I.D. are namedinventors on patent applications covering malaria-vectored vaccines and immunization regimes. The other authors have no financial conflicts officerest.	N/A	N/A	16/12/20
D	icks MD	adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice The relative magnitude of transgene-	2015 Scientific Reports	Jenner Institute Investigators, AJS and MGC are James Martin Fellows. This work has been funded by the Wellcome Trust (095540) with addi-tional funding from the Foundation for the National Institute of Health through the Grand Challenges in Global Health	MDJD, SCG, AVSH, and MGC are named inventors on a patent application describing the ChAdOx1 vector (US2015044766).	N/A	N/A	20/12/2020
		specific adaptive immune responses induced by human and chimpanzee		Initiative (HILLOSGCGHO). MDJD received additional funding from the Euro-pean Malaria Vaccine Development Association (EMVDA). AVSH is a Wellcome Trust Principal Research Fellow. EG and BC				

				This work has been funded by grants from the Foundation for the National Institute of Health				
				through the Grand Challenges in Global Health Initiative, with additional funding from the				
		A novel chimpanzee adenovirus vector		Wellcome Trust. MDJD received additional funding from the European Malaria Vaccine Development Association (EMVDA). MGCis a fellow of the Oxford Martin School Institute for				
		with low human seroprevalence:		Vaccine Design. SCG is a Jenner Investigator. AVSH is Director of the Jenner Institute and a	Competing interests: MDJD, SCG, AVSH, and MGC are named inventors on a patent application describing the ChAdY25/ChAdOx1 vector (GB PatentApplication No. 1108879.6). This does not alter			
0	ricks MD	improved systems for vector derivation and comparative immunogenicity	2012 Plos One	and analysis, decision to publish, or preparation of the manuscript.	the authors' adherence to all the PLoS ONE policies on sharing data and materials.	N/A	N/A	16/12/20
		Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus		This work was funded by the Wellcome Trust and the European Malaria Vaccine Devlopment				
		macaques by combining adenovirus,		Association, a European Commission FP6-funded consortium. S.J.D. is a Junior Research Fellow of	Disclosures: S.J.D, S.C.G, and A.V.S.H. are named inventors on patent applications covering malaria			
	raper SJ	poxvirus, and protein-in-adjuvant vaccines	2010 The Journal of Immunology	is also a Wellcome Trust Principal Research Fellow.	vectored vaccines and immunization regiments. S.C., M.N., A.F., and A.N. are employees of and/or shareholders in Okairòs, which is developing vectored vaccines for malarian and other diseases.	N/A	N/A	16/12/20
		Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever		This study was conducted with support from a grant from the Bill & Melinda Gates Foundation Grand Challenges Exploration! nitiative to GMW (OPP1096893) and a Wellcome Trust fellowship to				
E	rulal P	vaccine in cattle	2016 Vaccine	GMW (WT098635). B.C. and A.V.S.H. are Jenner Inves-tigators.	N/A	N/A	N/A	20/12/2020
				This work was supported by the UK Medical ResearchCouncil (grant number G0700735); the European MalariaVaccine Development Association, a European Commis-sion FP6-funded				
				consortium (LSHP-CT-2007-037506); the UK National Institute of Health Research through the Oxford				
		Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1		Biomedical Research Centre; the Wellcome Trust(084113/Z/07/Z); and by EVIMalaR funded by the Euro-pean Community's Seventh Framework Programme (FP7/2007–2013) (Grant agreement No.				
	lias SC	immunization and controlled malaria	2013 Immnunology	242095). AVSH and SID are Jenner Investigators; and SID is a UK MRCCareer Development Fellow (G1000527) and Lister Institute Prize Research Fellow.		NCT01373879, NCT01142765, NCT01003314, NCT01095055	N/A	20/12/2020
	ilas 3C	mecton	2013 IIIIIIIIIIIIII	(01000327) and lister instruce Fitze Research Fellow.		NC101003314, NC101033033	N/A	20/12/2020
					Dr. Ballou, Dr. De Ryck report personal fees and other support from GlaxoSmithKline outside the submitted work. Dr. Colloca, Dr. Cortese, Dr. Nicosia reports a pending patent related to			
					chimpanzee adenoviral-vector based filovirus vaccine (WO/2011/130627). Dr. Draper reports grant support from the UK Medical Research Council during the conduct of the study, and non-financial			
					support from GlaxoSmithKline/Okairos outside the submitted work. In addition, Dr. Draper reports			
				Supported by the Wellcome Trust, the United Kingdom Medi-cal Research Council, the United Kingdom Department for Inter-national Development, and the United Kingdom National Institute	pending patents related to viral vector immunogenic compositions (WO 2012042279 A3) and adenoviral vectors encoding a			
				for Health Research Oxford Biomedical Research Centre. The National Health Service Blood and	pathogen or tumor antigen (WO 2008122811 A2). Dr. Gilbert reports patents related to prime			
				Transplant and Public Health England provided funding for the competition EUSA. The ChAd3 vaccine was provided by the Vaccine Research Center of the National Institute of Allergy and	boost immunization with viral vectors. Dr. Hill reports a patent related to heterologous prime- boost immunization, licensed to Oxford BioMedica. Ms. Lella reports other support from the NIHR			
		A Monovalent Chimpanzee Adenovirus		Infectious Diseases (NIAID) and GlaxoSmithKline. MVA-BN Filo was produced under a con-tract (FBS-004-009) between the NIAID and Fisher BioServices and a contract (HHSN272200800044C)	during the conduct of the study. Dr. Levine reports grant support from Oxford University during the conduct of the study. Dr. Pollard reports grant support from the Wellcome Trust during the			
E	wer K	Ebola Vaccine Boosted with MVA	2016 New England Journal of Medicine	between the National Institutes of Health and Fisher Bioservices.	conduct of the study, and grant support from GlaxoSmithKline outside the submitted work.	N/A	N/A	20/12/2020
				The study was funded by greats from the LIV MRC the NINR through the Oxford Riemedical	Sarah Gilbert, Arturo Reyes-Sandoval, Anna Goodman, Geraldine O'Hara and Adrian Hill are named inventors on patent applications covering malaria vectored vaccines and immunization regimes			
				The study was funded by grants from the UK MRC, the NIHR through the Oxford Biomedical Research Centre, and the Wellcome Trust.AVSH was supported by a Wellcome Trust Principal	including: WO/2008/122811-Adenoviral vectors encoding a pathogen or tumour antigen and			
		Protective CD8 b T-cell immunity to human malaria induced by chimpanzee		Research Fellowship. A.L.G. wassupported by a grant from the MRC (G0600424). A.V.S.H., A.RS., S.J.D. and S.C.G. are Jenner Institute Investigators; A.V.S.H. is a Wellcome Trust and NIHR	WO/2008/122769-Adenoviral vector encoding malaria antigen. Authors from Okairos are employees ofand/or share holders in Okairos which is developing vectored malaria vaccines. All			
	wer K		2013 Nature Communications	SeniorInvestigator.	otherauthors declare no competing financial interests.	N/A	N/A	16/12/20
F	edosyuk S	Simian adenovirus vector production for		This work was supported by Merck KGaA, the UK MedicalResearch Council (grant MR/P017339/1), and the UK Engineeringand Physical Sciences Research Council (grant EP/R013756/1).ADD is				
		early-phase clinical trials: A simple		supported by the Wellcome Trust [grants 201477/Z/16/Zand 204826/Z/16/Z] and is a Jenner				
		method applicable to multiple serotypes and using entirely disposable product-		Investigator. The study wasperformed in collaboration between the University of Oxford and Merch KGaA; both partners reviewed the manuscript prior to sub-mission. The other funders had no	ADD, SJM, and SCG are named inventors on patent filings relating to the use of simian adenoviruses, but not directly related to the work described here. SCG is a founder of Vaccitech Ltd,			
		contact components	2019 Elselvier Vaccine	input to the design of the studyor decision to publish.	whichdevelops adenovirus-vectored vaccines.	N/A	N/A	10/12/2020
				UK Department of Health and Social Care, using UK Aid funding, managed by the UK National Institute for Health Research. This project was funded by the UK Department of Health and Social				
				Care (project number 16/107/01). The views expressed are those of the authors and not				
		Safety and immunogenicity of a		necessarily those of the Department of Health and Social Care. The work was supported by the UK National Institute for Health Research through the Oxford Biomedical Research Centre. The				
		candidate Middle East respiratory syndrome coronavirus viral-vectored		Coalition for Epidemic Preparedness Innovations provided funding for the extended 12 months of				
		vaccine: a dose-escalation, open-label,		follow-up in this study. This study was also partially supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (finance code 001). The pseudovirus	AH and SG are co-founders of, consultants for, and shareholders in Vaccitech, which is developing			
	olegatti P.M.	non-randomised, uncontrolled, phase 1	2020 The Lancet	neutralising antibody work was funded by a grant from the Korean Ministry of Health and Welfare (HI15C2971)	adenoviral vectored vaccines. PMF and TL are consultants for Vaccitech. All other authors declare no competing interests.	NCT03399578	N/A	18/12/20
	olegatu r.ivi.	u lai	2020 The Lancet	UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute		NC103333370	N/A	10/12/20
				for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and the German Center for Infection Research	vaccine candidate) and named as an inventor on apatent covering use of ChAdOx1-vectored			
				(DZIF), Partner site Gießen-Marburg-Langen. This work is funded by UK Research and Innovation	a patent application covering this SARS-CoV-2 vaccine and consultant to Vaccitech. PMF is a			
				(MC_PC_19055), Engineering and Physical Sciences Research Council (EP/R013756/1), Coalition for Epidemic Preparedness Innovations (CEPI), the National Institute for Health Research (NIHR), the				
				NIHR Oxford Biomedical Research Centre, and the German Center for Infection Research (DZIF),	coronavirus vaccines, and is a member of the WHO Strategic Advisory Group of Experts (SAGE).			
				Partner site Gießen-Marburg-Langen. Additional resources for study delivery were provided by NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre,	AVSH is a co-founder of and consultant to Vaccitech and is named as an inventor on a patent covering design and use of ChAdOx1-vectored vaccines. AF is a member of JCVI, Chair of the WHO		AZ mentioned in acknowledgements -	
		Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-		University Hospital Southampton NHS Foundation Trust; the NIHR Imperial Clinical Research	European Technical Advisory Group of Experts on Immunisation, an ex-officiomember of WHO		facilitated and funded some assays and reviewed the data from the study and	
		CoV-2: a preliminary report of a phase		Facility; and NIHR North West London, South London, Wessex, and West of England Local Clinical Research Networks and NIHR Oxford Health Biomedical Research Centre. PMF received funding	SAGE working group on COVID-19 vaccines, and acting director of National Institute for Health Research West of England Local Clinical Research Network. KMP reports grants from the NIHR	NCT04324606. The study is ongoing, and	the final manuscript before submission.	
F	olegatti P.M.	1/2, single-blind, randomised controlled trial	2020 The Lancet	from the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (finance code 001).	Imperial Biomedical Research Centre and Gilead Sciences, and personal fees from Sanofi Pasteur.	was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606.	In declaration of interests says royalties paid to AZ for vectors.	18/12/20
	olegatti PM	Safety and Immunogenicity of a Novel		Development of SARS-CoV-2 reagents was partially supported by the US National Institute of This research was funded by HAV Vaccines Ltd. The research was supported by the National Institutefor Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expresser	or the submitted work his reports brains from subsection dissociational control wearing and	=	•	
		Recombinant Simian Adenovirus		are those of theauthor(s) and not necessarily those of the NHS, the NIHR or the Department of	are co-founders of, consultants to and shareholders in Vaccitech plc which is developing			
		ChAdOx2 as a Vectored Vaccine	2019 MDPI	Health. This work was funded by the Wellcome Trust and the EMVDA (European Malaria Vaccine	adenoviralvectored vaccines.	NCT03027193	N/A	18/12/20
				Development Association, a European Commission FP6-funded consortium). The research leading				
				to these results has also received funding from the European Community's Seventh Framework Programme (FP7/2007–2013) under grant agreement No 242095. In addition, this work was				
				supported in part by the Division of Intramural Research, National Institutes of Allergy				
				and Infectious Diseases, National Institutes of Health, and also by the PATH Malaria Vaccine Initiative who support the GIA Reference Center. AVSH and SID are JennerInvestigators. AVSH is a				
		T cell responses induced by adenoviral		Wellcome Trust Principal Research Fellow. SJD is a MRC Career Development Fellow. The funders				
		vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization		had no role in study design, datacollection and analysis, decision to publish, or preparation of the manuscript, except that the design of the rabbit study and the GIA analysis was				
F	orbes EK	domain of C4b-binding protein	2012 Plos One	performed following discussion with PATH MVI.	Author contributions: . Contributed reagents/materials/analysis tools: SB ALGRJP FH.	N/A	N/A	16/12/20
		Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse						
		malaria model using a recombinant adenoviral vaccine in heterologous		Wellcome Trust and the European Commission(IC18-CT95-0019 TMR fellowship to J.S.) for				
	ilbert SC	prime-boost immunisation regimes	2002 Elselvier - Vaccine	support	N/A	N/A	N/A	14/12/20
G	iola A			A.G. is funded by the Wellcome Trust and by the Intramural Program of NIAID (NIH). B.R.H. is funded from the European Union Seventh Framework Programme FP7/2012-2106 under grant				
				agreement 316655 (VACTRAIN). A.V.S.H. is a Wellcome Trust and National Institute of Health				
				Research (NIHR) senior investigator. This work was in part funded by a Wellcome Trust Senior Investigator award (to A.V.S.H.) and a Wellcome Trust Enhancement award (to A.V.S.H.) for the				
				clinical trial and also was supported in part by the Intramural Research Program of NIAID (NIH) (to				
		Prime and target immunization protects against liver-stage malaria in mice	2018 Science Transitional Medicine	R.N.G. and S.U.). The clinical trial was supported in part by funding from the UK NIHR Oxford Biomedical Research Centre	submitted by the Oxford University Innovation Limited that covers prime and target vaccination with viral vectors	N/A	N/A	21/12/2020
				This work was supported primarily by grant G0600424 from the Medical Research Council (ALG) and in addition by Transmolbloc (EU FP7) and BBSRC(award number LDAD_P15820). SID and AVH		•	,	
				and in addition by Transmolbloc (EU FP7) and BBSRC(award number LDAD_P15820). SJD and AVH are Jenner Investigators. SJD is a MRC Career Development Fellow. AVH is a Wellcome Trust				
		A viral vectored prime-boost		Principal Research Fellow. ALG was an MRC clinical training fellow whilst she undertook this				
		immunization regime targeting the malaria Pfs25 antigen induces		research. The funders had no role in study design, data collection and analysis, decisionto publish, or preparation of the manuscript. http://www.mrc.ac.uk/index.htm. http://www.bbsrc.ac.uk/.				
G	ioodman AL	transmission-blocking activity	2011 Plos One	http://www.wellcome.ac.uk/.	N/A	N/A	N/A	16/12/20

			This study was supported by UKRI Engineering and Physical Sciences ResearchCouncil (EPSRC) award EP/R013756/1 (VaxHub), UKRI Biotechnology and BiologicalSciences Research Council				
			(BBSRC) Institute Strategic Programme and Core CapabilityGrants to The Pirbright Institute				
			(BBS/E/I/00007031, BBS/E/I/00007034, BBS/E/I/00007037 and BBS/E/I/00007039), and the Bill and Melinda Gates Foundationsupported Pirbright Livestock Antibody Hub' (Grant No. OPP1215550).				
			Developmentof SARS-CoV-2 reagents was partially supported by the NIAID Centers of Excellencefor				
	Evaluation of the immunogenicity of prime-boost vaccination with the		Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C andEPSRC Grant No. EP/S025243/1 to the Rosalind Franklin Institute. A.L., G.W., C.B., A.B., and V.M. are supported by				
	replication-deficient viral vectored		the UK Department for Environment Food & Rural Affairs. We thank V. Clark, H. Gray, and R. Snaith	S.C.G. and T.L. are named on a patent application covering ChAdOx1 nCoV-19. Theremaining			
	COVID-19 vaccine candidate ChAdOx1 nCoV-19	2020 Nature partner journals	for animal husbandry and the JennerInstitute Vector Core Facility for assistance, and The Pirbright Institute Animal ServicesTeam for animal care and provision of samples.		N/A	N/A	18/12/20
Granam 3	100 13	2020 Nature partner journals	BRH received funding from the European Union Seventh Framework Programme FP7/2012-2016		N/A	1970	10/11/10
	Development of a Molecular Adjuvant to		under grant agreement n° 316655 (VACTRAIN). Additional funding was provided by a Wellcome	A.V.S.H. is a named investigator on US 12/595 574 and UK PCT/GB2008/01262 novel adenovirus patent applications covering malaria vectored vaccines and immunisation regimens; A.V.S.H., A.J.S.,			
	Enhance Antigen-Specific CD8(+) T Cell		vector core facility. Further funding was provided by a Gates Grand Challenges in Global Health	M.J.C. and B.R.H. are named investigators on UK PCT/GB2014/053596, a novel molecular adjuvant			
Halbroth BR	Responses	2018 Scientific Reports	award through the Foundation for NIH (to AVSH). This work was supported by the EMVDA (European Malaria Vaccine Development Association), a	application.	N/A	N/A	10/12/2020
			European Commission (EC) FP6-funded consortium (LSHP-CT-2007-037506); the UK National				
	Combining viral vectored and protein-in-		Institute of Health Research through the Oxford Biomedical Research Centre (NIHR-BRC) (A91301 Adult Vaccine); the Wellcome Trust (084113/Z/07/Z); and EVIMalaR, an EC FP7-funded programme				
	adjuvant vaccines against the blood-		(Grant agreement No. 242095). The GIA work was supported by the PATH Malaria Vaccine Initiative	D.D., J.J.I., S.C.dC., A.V.S.H., and S.J.D. are named inventors on patent applica-tions covering			
Hodeson SH	stage malaria antigen AMA1: report on a phase 1a clinical trial	2014 Molecular Therapy	and the Intramural Program of the National Institutes of Health, National Institute of Allergy and	malaria vaccines and immunization regimens. A.N. is an employee of and/or shareholder in Okairòs, which is developing vectored vaccines for malaria and other diseases.	NCT01351948	N/A	20/12/2020
nougson an	Evaluation of the efficacy of ChAd63-	2014 Molecular Therapy			NC101331540	N/A	20/12/2020
	MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP		This work was supported by the PATH MalariaVaccine Initiative, the United Kingdom National Institute of Health Re-search, through the Oxford Biomedical Research Centre (grant A91301, Adult	A. V. S. H. and S. C. G. are named inven-tors on patent applications covering malaria vectored			
	against controlled human malaria		Vaccine), and the Wellcome Trust (grants 084113/Z/07/Z and45488/Z/05 to A. V. S. H. and grant	inOkairos, whichis developing vectored vaccines formalariaandother diseases. All other authors			
Hodgson SH	infection in malaria-naive individuals	2015 The Journal of Infectious Diseases	097940/Z/11/Z to S. H. H.). Supported by a Medical Research Council (MRC) UK Development Clinical Scheme award	report no potential conflicts. Dr. Colloca, Dr. Folgori, Dr. Cortese, and Dr. Nicosia are named inventors on patent applications	NCT01623557	N/A	20/12/2020
			(G0701694); by the Wellcome Trust, the Oxford NHIRBRC, and the U19 grant (2U19AI082630-06, to	covering hepatitisCvirus-vectored vaccines and chimpanzee adenovirus vectors (WO 2006133911			
	Chronic hepatitis C viral infection subverts vaccine-induced T-cell		C.K. and P.K.); by an MRC CASE studentship (to L.S.). E.B. is funded as an MRC Senior ClinicalScientist and is supported by the Oxford NHIR BRC, the Oxford Martin School, and the	[A3] hepatitis C virus nucleic acid vaccine, WO 2005071093 [A3] chimpanzee adenovirus vaccine carrier, WO 03031588 [A2] hepatitis C virus vaccine). Dr. Hill is a coinventor on patent filings and			
Kelly C	immunity in humans	2016 Hepatology	Jenner Institute.		NCT01094873, 2008-006127-32)	N/A	20/12/2020
			This work was supported by an award from the European and Developing Countries Clinical Trials Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium				
			(MVVC), a four and a half year integrated project funded by the European and Developing				
			Countries Clinical Trials Partnership (EDCTP, grant number IP.2008.31100.001). N.I.V. is an employee of the European Vaccine Initiative (EVI). E.V.I. is the coordinator of the EDCTP				
			funded MVVC project (grant number IP.2008.31100.001). E.V.I. supports salaries of the MVVC				
			project in kind. The work was also supported by the UK National Institute of Health Research through the Oxford Biomedical Research Centre (http://www.oxfordbrc.org/) [A91301 Adult				
	Translating the immunogenicity of prime-		Vaccine], the Wellcome Trust (http://www.wellcome.ac.uk/) (084113/Z/07/Z) and the Medical				
	boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to		Research Council. S.H.H. holds a Wellcome Trust research training fellowship (097940/Z/11/Z). The funders had no role in study design, data collection and analysis,	A.V.S.H. is a named inventor on patent applications on malaria vectored vaccines and immunization regimens. Authors from Okairòs are employees of and/or shareholders in Okairòs,			
Kimani D	malaria-endemic populations	2014 Molecular Therapy	decision to publish, or preparation of the manuscript.	which is devel-oping vectored vaccines for malaria and other diseases.	N/A	N/A	16/12/20
	Immunity against heterosubtypic influenza virus induced by adenovirus						
	and MVA expressing nucleoprotein and		AvL was funded by a fellowship of theDr. Saal van Zwanenberg Stichting. Dr. Lambe is supported by				
Lambe T	matrix protein-1	2013 Scientific Reports	the Oxford Martin School.SCG is a Jenner Investigator. This work has been funded by a grant from the Wellcome Trust (095540/Z/11/Z) with additional	N/A	N/A	N/A	16/12/20
	Comparative assessment of vaccine		funding by the Rhodes Trust and a Nuffield Department of Medicine Studentship to support RJL				
	vectors encoding ten malaria antigens identifies two protective liver-stage		and EVIMalR studentship to support AMS. AVSH is a Jenner Institute Investigator; AJS is a James Martin Fellow. CJJ was supported by a grant of the European Community's Seventh Framework	AVSH is a named investigator on US 12/595 574 and UK PCT/GB2008/01262 novel adenovirus patent applications covering malaria vectored vaccines and immunization regimens: RJL AMS, CJJ.			
Longley RJ	candidates	2015 Scientific Reports	Programme (FP7/2007-2013) under grant agreement number 242095.	SMK, AJS and AVSH are named investigators on filed patent (1318084.9) for novel malaria antigens	N/A	N/A	20/12/2020
			Funding for manufacture and quality control release and stability studies of Sanaria's PfSPZ challenge was provided by the National Institute of Allergy and Infectious Diseases				
			(http://www.niaid.nih.gov.) under grant R44AI058375 (Universal Attenuated Malaria Sporozoite				
			Vaccine and Challenge System). The present work was funded by a grant from the Wellcome Trust (grant 095540/Z/11/Z) to A.V.S.H., with additional funding by the Rhodes Trust and a Nuffield				
			Department of Medicine Studentship to support R.J.L. The human CHMI study (VAC049) was				
			supported by the UK National Institute of Health Research through the Oxford Biomedical Research Centre (http://www.oxfordbrc.org/) (A91301 adult vaccine program) and the Wellcome Trust				
	Assessment of the Plasmodium		(grant 084113/Z/07/Z). B.R.H. receives funding from the European Union Seventh Framework	A.V.S.H. is a named investigator on novel adenovirus patent applications U.S. 12/595 574 and UK			
	falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria		Programme FP7/2012-2016 under grant agreement 316655 (VACTRAIN). S.H.H. is a Wellcome Trust Clinical Research Fellow (grant 097940/Z/11/Z). A.V.S.H. is a Jenner Institute Investigator, and A.J.S.	PCT/GB2008/01262, covering malaria vectored vaccines and immunization regimens. R.J.L., A.J.S., and A.V.S.H. are named investigators on patent PCT/GB2014/053077. identifying novel malaria			
Longley RJ	Vaccine	2017 Infection and Immunity	is a James Martin Fellow.	vaccine antigens.	NCT01465048	N/A	21/12/2020
			This report is independent research funded by the UKDepartment of Health and Social Care				
			through Innovate UK"New vaccines for globalepidemics: development and manufacture"grant No.				
			972216 (A.RS.), and also fundedfrom an ODA budget (Global Health (ODA), 16/107/05—Design, development and GMP manufacture of a Zika vaccine) (A.H.P. and A.R-S). The views expressed in	A.RS. and C.LC. are co-inventors of the Zika vaccines described n this manuscript, filed by Oxford			
	Rational Zika vaccine design via the		thispublication are those of the author(s) and not necessarily those of the Department of Health and Social Care. We also acknowledge funding by the UK Medical ResearchCouncil (MC_UU_12014	University Innovation Limited in the International Patent Application No. PCT/GB2017/052220 Zika			
	modulation of antigen membrane anchors in chimpanzee adenoviral			Vaccine; A.V.S.H. and S.C.G. are co-inventors on a patent application (WO/2012/1/22//) on the ChAdOx1 viral vectorfiledby Oxford University Innovation. The remaining authors declare no			
López-Camacho C	vectors	2018 Nature Communications	Newton Fund grant, Gavin Screaton is a Wellcome Trust Senior Investigator.	competing interests.	N/A	N/A	21/12/2020
McMahon M	Vaccination With Viral Vectors			The Icahn School of Medicine at Mount Sinaihas filed patent applications regarding influenza virus vaccines withFK being aninventor. SG is an inventor on patents covering ChAdOx1 and MVA-NP+			
	Expressing Chimeric Hemagglutinin, NP		The study was funded by an MRC Biomedical Catalyst DPFS_DCS award (MR/N006372/1). In addition, this study was partially funded by the NIAID Centers of Excellence for Influenza Research	M1, filed and owned by the University of Oxford, and is a co-founder of and consultantto Vaccitech,			
	and M1 Antigens Protects Ferrets Against Influenza Virus Challenge	2019 Vaccine		a University of Oxford spin-out company which is undertaking advanced clinical development of viral vectored influenza vaccines.	N/A	N/A	10/12/2020
			This work was supported by a Strategic Primer grant award from the European and Developing				
	Safety and Immunogenicity of Malaria		Countries Clinical Trials Partnership (EDCTP, grant number SP.2011.41304.025); with co-funding from Swedish International Development Cooperation Agency (Sida); UK Medical Research	The following authors have declared that no conflict of interest exists: VM, SR, EK, AmN, FO, CB, GB, YJ, RR, NV, FD, OL, AL, BF, BK, BC, SG, EC, KE, EI, and MA. AH is a named inventor on patent			
	Vectored Vaccines Given with Routine		Council; Irish Aid, Department of Foreign Affairs and Trade, Ireland; and Bundesministerium	applications on malaria vectored vaccines and immunization regimens. RC and AIN are employees			
	Expanded Program on Immunization Vaccines in Gambian Infants and		pro-ject under phase two of Malaria Vectored Vaccines Consortium (MVVC 2). Additional funding	and/or shareholders in ReiThera, which develops vectored vaccines for malaria and other diseases. The authors declare that the research was conducted in the absence of any commercial or financial			
	Neonates: A Randomized Controlled			relationships that could be construed as a potential conflict of interest. The reviewer AL declared a			
Mensah VA	Trial	2017 Frontiers in Immunology	Health Research	past collaboration with four of the authors, OL, NV, FD, and AH, to the handling Editor. We have the following interests. Adrian V.S. Hill is a named inventor on patent applications and	NCT02083887	N/A	21/12/2020
				patents on malaria vectored vaccines and immunisation regimes including the following			
			This study was supported by an award from the European and Developing Countries Clinical Trials	(WO2008/122769, Adenoviral vector encoding malaria antigen; and WO 2008/122811 Novel adenovirus vectors). Egeruan Imoukhuede and Ines Petersen were employees of EVI at the time of			
	Safety, Immunogenicity and Efficacy of		Partnership (EDCTP) and was performed by the Malaria Vectored Vaccines Consortium (MVVC), an	the study, which supports the development and testing of malaria vaccines. Nicola Viebigis an			
	Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against		integrated project funded by EDCTP (grantnumberIP.2008.31100.001).Co-funding was also provided by the Medical Research Council UK, the Swedish International Development Cooperation	employee of EVI and Odile Leroyis executive director of EVI. Authors from Rei Thera (formerly Okairos) are employees of and/or shareholders in Rei Thera, which is developing vectored vaccines			
	Plasmodium falciparum Infection in		Agency (Sida) and Irish Aid. The work was also supported by the Dakar University Cheikh Anta	for malaria and other diseases. Alfredo Nicosia was employed by Rei Thera (formerly Okairos) at	PACTR201-303-000-499-409. (African		
Mensah VA	Adults in Senegal	2016 Plos One	Diop. This work is published with the permission of the Director of the Kenya Medical Research Institute,	the time of thestudy.	Pan Trial Registry)	N/A	21/12/2020
	Protective efficacy of a novel simian		and wassupported by the Intramural Research Program of the National Institute of Allergyand				
	adenovirus vaccine against lethal MERS- CoV challenge in a transgenic human		Infectious Diseases (NIAID), National Institutes of Health (NIH) and a grant fromthe UK Medical Research Council Confidence in Concept scheme to GMW throughthe LSTM Tropical Infectious	S.C.G. is a co-founder of, consultant to and shareholder inVaccitech plc, which is developing a			
Munster VJ	DPP4 mouse model	2017 Npj Vaccines	Disease Consortium	vectored MERS vaccine. Remaining authors declares that they have no competing financial interests.	N/A	N/A	21/12/2020

	Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior		This work was supported by an award from the European and Developing Countries Clinical Trials				
	to evaluation of a candidate malaria		Partnership (EDCTP) and wasperformed by the Malaria Vectored Vaccines Consortium (MVVC), an				
Nébié I	vaccine regimen based on viral vectors	2014 Clinical and Vaccine Immunology	integrated project funded by EDCTP (grant numberIP.2008.31100.001).	N/A Potential conflicts of interest: S. G., A. RS., A. G., G. O. H., and A. H.are named inventors on patent	N/A	N/A	16/12/20
			Financial support. This work was supported by an Experimental Medicine grant from the UK	applications covering malaria-vectoredvaccines and immunization regimes. Authors from Okairos			
			Medical Research Council (grant number G0502018) with additional support from the UK National	are employeesof and/or shareholders in Okairos, which is developing vectored malariavaccines. All			
	Clinical assessment of a recombinant simian adenovirus ChAd63: a potent		Institute for Health Research Oxford Biomedical Research Centre and the Wellcome Trust. No funding bodies had any role in study design, data collection and	other authors report no potential conflicts.All authors have submitted the ICMJE Form for Disclosure of PotentialConflicts of Interest. Conflicts that the editors consider relevant to			
O'Hara GA	new vaccine vector	2012 The Journal of Infectious Diseases	preparation of the manuscript.	thecontent of the manuscript have been disclosed.	NCT00890019	N/A	16/12/20
	Prime-boost vaccination with		This work was funded by the European and Developing Countries Clinical TrialsPartnership grant	A.V.S.H., A.N., and S.G. are listed as inventors on patent filings related to heterologous prime-boost	,		
	chimpanzee adenovirus and modified		number IP.2008.31100.001, to the Malaria Vectored Vaccines Consortium(MVVC), and coordinated	immunization and specific malaria vaccines. E.B.I. was an employee of EVI at the time of this study,			
	vaccinia Ankara encoding TRAP provides partial protection against Plasmodium		by the European Vaccine Initiative (EVI). P.B. is jointly funded by the U.K. Medical Research Council (MRC) and the U.K. Department for International Development(DFID) under the MRC/DFID	which supports the development and testing of malaria vaccines. N.K.V. is an em-ployee of EVI, and O.L. is executive director of EVI. A.N. is an employee of Okairos and consultsfor GlaxoSmithKline.	I		
Ogwang C	falciparum infection in Kenyan adults	2015 Science Transitional Medicine	Concordat agreement.	The other authors declare no competing interests.	NCT01666925, PACTR 201202000356208	N/A	20/12/2020
	Safety and immunogenicity of		This work was performed by the Malaria Vectored Vaccines Consortium (MVVC), a four year integrated project funded by the European and DevelopingCountries Clinical Trials Partnership	Competing Interests: AH is a named inventor on the following patent applications on malaria			
	heterologous prime-boost immunisation		(EDCTP). The work was also supported by the UK National Institute of Health Research through the	vectored vaccines and immunization regimes (WO2008/122769,Adenoviral vector encoding malaria	Pactr.org PACTR2010020001771828		
	with Plasmodium falciparum malaria		Oxford BiomedicalResearch Centre (http://www.oxfordbrc.org/) [A91301 Adult Vaccine], the	antigen; and WO 2008/122811 Novel adenovirus vectors). Authors from Okairo's are employees of	Pactr.org PACTR201008000221638		
	candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian		Wellcome Trust (http://www.wellcome.ac.uk/) [084113/Z/07/Z] and theMedicalResearch Council. The funders had no role in study design, data collection and analysis, decision to publish, or		ClinicalTrials.gov NCT01373879ClinicalTrials.gov		
Ogwang C	and Kenyan adults	2013 Plos One	preparation of the manuscript.	and materials.	NCT01379430	N/A	16/12/20
Payne RO			This work was supported by a UK Medical Research Council (MRC) grant (number G1100086). The study was also supported in part by UK National Institute of Health Research (NIHR) infrastructure				
			through the NIHR Oxford Biomedical Research Centre and the Wellcome Trust (084113/Z/07/Z). DL				
			was supported by the Rhodes Trust. TAR holds a Wellcome Trust Research Training Fellowship	S.C. de Cassan, M.K. Higgins, A.V.S. Hill, and S.J. Draper are named inventors on patent applications	i		
			(108734/Z/15/Z). SCdC was a PhD student supported by the European Malaria Vaccine Development Association, a European Commission Framework Programme 6-funded consortium	(patent nos. GB1413530.5, GB1016471.3, and WO/2008/122811) covering malaria vaccines and immunization regimens. A. Nicosia was an employee of and shareholder in Okairòs (since acquired			
			(grant LSHP-CT-2007-037506). TDO is sup-ported by the Wellcome Trust (WT 098051). JSM is	by GlaxoSmithKline), which is developing vectored vaccines for a number of diseases. T. Jørgensen			
	Human vaccination against Plasmodium vivax Duffy-binding protein induces		supported by an NHMRC Practitioner Fellowship (number 1041802). AVSH and SJD are Jenner Investigators. SJD is a Lister Institute Research Prize Fellow and a Wellcome Trust Senior Fellow	and W.A. de Jongh are employees of, and W.A. de Jongh is a shareholder in, ExpreS2ion Biotechnologies, which has developed and is marketing the ExpreS2 cell expression platform. C.E.			
	strain-transcending antibodies	2017 JCI Insight	(grant number 106917/Z/15/Z).	Chitnis is a named inventor on a patent covering PvDBP_RII (patent no. WO/1996/040766).	NCT01816113	N/A	21/12/2020
				S.J. Draper is a named inventor on patent applications relating to RH5 and/or other malaria			
			This work was supported by funding from the European Union Seventh Framework Programme	vaccines and immunization regimens; is a cofounder of, shareholder in, and consultant for			
			(FP7/2007-2013) under the grant agreement for MultiMalVax (number 305282). The study was also supported in part by UK NIHR infrastructure through the NIHR Oxford Biomedical Research Centre	 SpyBiotech; and declares research funding support from Pfizer and GSK BioPharm. A.D. Douglas, G.J. Wright, and A.V.S. Hill are named inventors on patent applications relating to RH5 and/or other 			
			the MAVARE-CA program funded by Danida (the Consultative Committee for Development	malaria vaccines and immunization regimens. L. Siani and S. Di Marco are employees of ReiThera			
			Research, Denmark); and the Wellcome Trust (grant numbers 084113/Z/07/Z and 206194). The GIA work was supported by the United States Agency for International Development (USAID) and the	(formerly Okairos), which is currently developing vectored vaccines for a number of diseases. J.			
			Intramural Program of the NIH, National Institute of Allergy and Infectious Diseases. DGWA holds a	Ashfield is a director of Ducentis and holds shares in the company, which is developing a therapy			
			UK MRC iCASE PhD Studentship (MR/K017632/1); JSM is supported by a National Health and	for autoimmune disease. A.M. Minassian has an immediate family member who is an inventor on			
	Human vaccination against RH5 induces neutralizing antimalarial antibodies that		Medical Research Council (NHMRC) Practitioner Fellowship (10418020); ADD held a Wellcome Trus Training Fellowship for Clinicians in Basic Sciences (089455/2/09/z): SB, AVSH, and SJD are Jenner	t patents relating to KHS and/or other maiaria vaccines and immunization regimens and who is a cofounder of, shareholder in, and consultant for SpyBiotech. S. Biswas is a cofounder and CEO of,			
	inhibit RH5 invasion complex		Investigators; and SJD is a Lister Institute Research Prize Fellow and a Wellcome Trust Senior Fellow	and shareholder in, SpyBiotech and is a contributor in a patent application relating to			
Payne RO	interactions	2017 JCI Insight	(106917/Z/15/Z)	multimerisation technology. J. Jin is a cofounder of and shareholder in SpyBiotech. Competing Interests: Authors MLC, GJPF, XC and MAFK are either inventors or contributors to a	NCT02181088	N/A	21/12/2020
	Dry-coated live viral vector vaccines			patent filings related to the NanopatchTM technology, that is now licensed to Vaxxas Pty Ltd. These			
	delivered by nanopatch microprojections retain long-term		This work has been supported by a UK Medical Research Council Capacity Building Studentship (G0600311, www.mrc.ac.uk) and by the Bill and Melinda Gates Foundation (003436,	are detailed in Supporting Information - Table S2. Authors MLC, SRY, GJPF and MAFK have employment with Vaxxas. MAFKis a member of the Vaxxas board. There are no further patents,			
	thermostability and induce transgene-		www.gatesfoundation.org). The funders had no role in study design, data collection and analysis,	products in development or marketed products to declare. This does not alter the			
Pearson FE	specific T cell responses in mice	2013 Plos One	decision to publish, orpreparation of the manuscript.	authors'adherence to all the PLOS ONE policies on sharing data and materials.	N/A	N/A	16/12/20
	Induction of CD8(+) T cell responses and						
	protective efficacy following microneedle-mediated delivery of a live		This study was funded by Enterprise Ireland (CFTD07/117,http://www.enterprise-ireland.com), Science Foundation Ireland (NAP156andNAP170,www.sfi.ie) and the Medical Research Coun-				
Pearson FE	adenovirus-vectored malaria vaccine	2015 Vaccine	cil,United Kingdom (G0600311,www.mrc.ac.uk).	None	N/A	N/A	20/12/2020
	A multi-antigenic adenoviral-vectored						
	vaccine improves BCG-induced protection of goats against pulmonary		The study was funded by the European Community's 7th Framework Programme (FP7-KBBE- 2007-1-3-04: TB-STEP project under grant agreement212414). The funders had no role in				
	tuberculosis infection and prevents		study design, data collection and analysis, decision to publish, or preparation of the				
Pérez de Val B	disease progression Safety and High Level Efficacy of the	2013 Plos One	manuscript.	N/A . V. S. H. and S. C. G. are named inven-tors on patent applications covering malaria vectored	N/A	N/A	16/12/20
	Combination Malaria Vaccine Regimen			vaccines and immu-nization regimens. D. M., M. L., and R. W. B. are employees of GSK, which			
	of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia		This work was supported by the PATH Malaria Vaccine Initiative and by the United Kingdom NIHR.	isdeveloping vectored vaccines for malaria and other diseases. S. N. F. acts onbehalf of the University of Southampton/University Hospital SouthamptonNational Health Service Foundation			
	Ankara Vectored Vaccines Expressing		through the NIHROxford Biomedical Research Centre, the Southampton NIHR WellcomeTrust	trust as chief and principal investigatorfor clinical trials sponsored by vaccine manufacturers,			
Rampling T	ME-TRAP	2016 The Journal of Infectious Diseases	Clinical Research Facility, and the Imperial College NIHR WellcomeTrust Clinical Research Facility.	including GSK, but receives no personal payments for the work.	NCT01883609	N/A	20/12/2020
			This work was funded primarily by the PATH Malaria VaccineInitiative (MVI); in addition, the work				
			was supported by the United Kingdom NationalInstitute of Health Research (NIHR) infrastructure,	A.V.S.H. and S.C.G. are named inventors on patent applications and patents relating to malaria			
	Safety and efficacy of novel malaria		through the NIHR OxfordBiomedical Research Centre, the Southampton NIHR Wellcome Trust Clinical ResearchFacility, and the Imperial College NIHR Wellcome Trust Clinical Research Facility;	vectored vaccines and immunization regimens. D.M.,M.L., and R.W.B are employees of GSK, which is developing vaccines for malaria and other diseases. S.N.F. acts on behalf of the University of			
	vaccine regimens of RTS,S/AS01B alone,		thisarticle/paper/report presents independent research funded by PATH MVI and supported by the	Southampton/UniversityHospital Southampton NHS Foundation trust as chief and principal			
Rampling T	or with concomitant ChAd63-MVA- vectored vaccines expressing ME-TRAP	2018 Nature partner journals	NIHR CRF and BRC at Imperial College Healthcare NHS Trust. Theviews expressed are those of the author(s) and not necessarily those of PATH MVI. theNHS, the NIHR, or the Department of Health.		NCT02252640	N/A	18/12/20
			, , , , , , , , , , , , , , , , , , , ,	The lates		•	
	Prime-boost immunization with adenoviral and modified vaccinia virus		Work in the Oxford malaria vaccine program is supported by the Wellcome Trust, the UK Medical Research Council, the UK National Institute for Health Research through the Oxford Biomedical				
	Ankara vectors enhances the durability		Research Centre, the European Commission, the Gates Foundation through a Grand Challenges in				
Reves-Sandoval A	and polyfunctionality of protective malaria CD8+ T-cell responses	2010 Human Vaccines	Global Health award from the Foundation for NIH, the European Malaria Vaccine Initiative, the Jenner Vaccine Foundation and the European and Developing Countries Clinical Trials Partnership.	N/A	N/A	N/A	10/12/2020
ncycs-salluoval A	mount Cour I real responses	2020 Hamilan Vaccines	We thank the Jenner Institute's vector core facility for providing the viral-vectored vaccines	No.	140	19/0	20/ 22/2020
			and Dr Helen McShane for providing the ad-enoviral and MVA vectors expressing antigen 85A.				
			We are also grateful to Andrew Williams for providing the P. berghei parasites and the NIH tetramer facility (MHC tetramer core facility, Emory University Vaccine Center, Atlanta, GA) for				
			preparing the Pb9 tetramer. The transgenic parasites were kindly provided by Dr Oliver Billker				
			from Wellcome Trust Sanger Institute, Hinxton, UK. This work was funded by Wellcome Trust Principal Research Fellowship award: Grant Number: 076438: The National Institute for Health				
	Mixed vector immunization with		Research Oxford Biomedical Research Centre Program and Grand Challenges in Global Health.				
	recombinant adenovirus and MVA can improve vaccine efficacy while	The American Society of Good 9, Coll	A.RS. is a Scientific Leadership Fellow of the Nuffield Department of Medicine and a Wellcome Trust Fellow. C.S.R. is supported by Oxford Biomedical Research Center, The Oxford				
Reyes-Sandoval A	decreasing antivector immunity	2010 Therapy	Martin School and Meningitis UK.	N/A	N/A	N/A	16/12/20
	Single-dose immunogenicity and protective efficacy of simian adenoviral		The work was supported by a Wellcome Trust Principal Research Fellowship award grant number				
Reyes-Sandoval A	protective efficacy of simian adenoviral vectors against Plasmodium berghei	2008 European Jounnal of Immunology	The work was supported by a Wellcome Trust Principal Research Fellowship award grant number 076438 to A.V.S.H.	N/A	N/A	N/A	16/12/20
	-						

F	Rollier CS			This work was funded by a grant from the Foundation for the National Institutes of Health through				
				the Grand Challenges in Global Health Initiative of the Gates Foundation, with additional support from the Wellcome Trust. Non-human primate studies were supported by National Center for				
				Research Resources (NCRR) grant # P51 RR000167, and were conducted at a facility constructed				
				with support from grants RR15459 and RR020141. The authors wish to acknowledge the expert				
				contribution of Dr Matthew G. Cottingham, and the expert help provided by the Animal Services Unit, and the Immunology Services Unit of the Wisconsin National Primate Research Center, in				
				particular D. Watkins and E. Rakasz. CR is supported by the NIHR Biomedical Research Centre,				
		Modification of Adenovirus vaccine		Oxford. CR, SGC and AVSH are Jenner Institute Investigators and AVSH is a Wellcome Trust and NIHR Senior Investigator. The funding sources had no involvement in study design; collection,				
		vector-induced immune responses by		analysis and interpretation of data, in the writing of the report and in the decision to submit the	A.V.S.H. and S.G.C. are names as co-inventors on patents related to recombinant viral vectors for			
		expression of a signalling molecule	2020 Nature	article for publication. he work was funded by a Wellcome Trust Career Development Fellowship award, grant number	malaria and other indications.	N/A	N/A	18/12/20
				097395/Z/11/Z, to A.RS, who is also a Jenner Investigator and an Oxford Martin Fellow. Funding				
		Rational development of a protective P.		was also provided by the Medical Research Council, through a DPFS grant (MR/N019008/1) to A.R S. Ahmed M. Salman was funded by EVIMalaR's Program funding (FP7/2007–2013) under grant				
		vivax vaccine evaluated with transgenic		agreement N° 242095. Adrian Hill is supported by a Wellcome Trust grant number 095540/Z/11/Z				
5	alman AM	rodent parasite challenge models	2017 Scientific Reports	and is a Jenner Investigator and an Oxford Martin Fellow.	N/A	N/A	N/A	21/12/2020
		A Multi-Filovirus Vaccine Candidate: Co- Expression			Teresa Lambe and Sarah Gilbert are Jenner Investigators. All other authors declare noconflicts of interest. Views expressed are those of the authors and do not necessarily reflect those of the			
		of Ebola, Sudan, and Marburg Antigens		This research was funded by Innovate UK (Novel multivalent vaccines against haemorrhagic	employinginstitutions. The funders had no role in the design of the study; in the collection,			
	iebastian S	in a Single Vector	2020 MDPI	fevers,971510) and MRC (Confidence in Concept CiC 2015-16, MC_PC_15040, Liverpool School of Tropical Medicine).	analyses, or interpretation ofdata; in the writing of the manuscript, or in the decision to publish the results.	N/A	N/A	18/12/20
3	sebastian S	Single vector	2020 MDPI	This work was supported by the European Malaria Vaccine Development Association (EMVDA), a	results.	N/A	N/A	18/12/20
				European Commission FP6-funded consortium (http://www.emvda.org/) [LSHP-CT-2007-037506];				
				the UK National Institute of Health Research through the Oxford Biomedical Research Centre (http://www.oxfordbrc.org/) [A91301 Adult Vaccine]; and the Wellcome Trust				
				(http://www.wellcome.ac.uk/) [084113/Z/07/Z]. The GIA work was supported by the PATH				
				MalariaVaccineInitiative (MVI; http://www.malariavaccine.org/) and the Intramural Program of the National Institutes of Health, National Institute of Allergyand InfectiousDiseases	 Competing Interests: AJS, MDJD, SCG, AVSH and SJD are named inventors on US 12/595 574 and UK PCT/GB2008/01262, US 12/595 351 and UK PCT/GB2008/01271 novel adenovirus patent 			
				(http://www.niaid.nih.gov/Pages/default.aspx). CJAD holds a Wellcome Trust Research Training	applications covering malaria vectored vaccines and immunization regimes. This does not alter our			
		Phase Ia clinical evaluation of the safety		Fellowship (RTEIO); SCG, AVSH and SJD are JennerInvestigators; AVSH was supported by a	adherence to all the PLoS ONEpolicies on sharing data and materials. Authors from Okairo's are			
		and immunogenicity of the Plasmodium		Wellcome Trust Principal Research Fellowship [45488/Z/05]; and SJD is a UK Medical Research	employees of and/or shareholders in Okairos, which is developing vectored vaccines for malaria			
5	Sheehy SH	falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors	2012 Plos One	Council CareerDevelopment Fellow [G1000527]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	and other diseases. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials.	NCT01095055	N/A	16/12/20
				This work was supported by the European Malaria Vaccine Development Association, a European				
				Commission FP6-funded consortium (LSHP-CT-2007-037506); the UK Medical Research Council (grant no. G0700735); the UK National Institute of Health Research through the Oxford				
				Biomedical Research Centre (A91301 Adult Vaccine), and the Southampton NIHR Wellcome Trust				
				Clinical Research Facility; the Wellcome Trust (084113/Z/07/Z); and EVIMalaR, an European				
				Commission FP7-funded programme (grant agreement no. 242095). The growth inhibitory				
				activity work was sup-ported by the PATH Malaria Vaccine Initiative and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.				
				S.C.G., A.V.S.H., and S.J.D. are Jenner Investigators; A.V.S.H. was supported by a Wellcome Trust Principal Research Fellowship (45488/Z/05): C.J.A.D. holds a Wellcome Trust Research				
		ChAd63-MVA-vectored blood-stage		Training Fellowship (094449/Z/10/Z); and S.J.D. is a UK Medical Research Council Career				
		malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against	The Assessment Section of Section 6 Self.	Development Fellow (G1000527). The funders had no role in study design data collection and	I			
5	Sheehy SH	mosquito bite challenge in humans	2012 Therapy	analysis, decision to publish, or prepa-ration of the manuscript. A.D.D., S.C.G., AUS.C.H., and S.J.D.	N/A	N/A	N/A	16/12/20
				are named inventors on patent applications covering malaria-vectored vaccines and immunization This work was supported by the UK Medical Research Council (MRC) (grant number G0700735), the	e '	,	,	* * * * * * * * * * * * * * * * * * * *
				European Malaria Vaccine Development Association (EMVDA), a European Commission FP6- funded consortium (LSHP-CT-2007-037506), the UK National Institute of Health Research through				
				Oxford Biomedical Research Centre (A91301 Adult Vaccine) and the Wellcome Trust				
				(084113/Z/07/Z). The GIA work was supported by the PATH Malaria Vaccine Initiative (MVI) and the	e e			
				Intramural Program of the National Institues of Health, National Institue of Allergy and Infectious Diseases. S.C.G., A.V.S.H, and S.J.D. are Jenner Investigators; A.V.S.H. was supported by a				
				Wellcome Trust Principal Research Fellowship (45488/Z/05) and S.J.D. is a MRC Career				
		Phase Ia clinical evaluation of the		Development Fellow (G1000157). A.R.W., S.C.G., A.V.S.H., and S.J.D. are named inventors on				
		Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA		patent applications coverin malaria vectored vaccines and immunization regimes. Authors from Okairòs are employees of and/or shareholders in Okairòs which is developing vecotred vaccines fo				
S	iheehy SH	vaccine vectors	2011 The Journal of Immunology	malaria and other diseases.	N/A	N/A	N/A	16/12/20
				This work has been funded by grants from the Foundation for the National Institute of Health through the Grand Challenges in Global Health Initiative(HILLOSGCGHO) with additional funding				
				from the Wellcome Trust (095540/Z/11/Z). Non-human primate studies were supported by				
				National Center for ResearchResources (NCRR) grant#P51 RR000167, and was conducted at a				
				facility constructed with support from grants RR15459 and RR020141. The funding bodies didnot have a role in the study design, data collectionand analysis, decision to publish or preparation of	AVSH is a named inventor on WO/2008/122811-Adenoviral vectors encoding a pathogen or			
				the manuscript. Co-authors S. Capone, S. Colloca, AF, RC andAN are employees of Okairos.	tumour antigen and WO/2008/122769-Adenoviral vector encoding malaria antigen. S. Colloca, AF			
				Okairos provided support in the form of salaries for the authors, but did not have any	RC, and AN are named inventors on patent application WO 2005071093 (A3)-Chimpanzee			
		Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP		additional role in the study design, datacollection and analysis, decision to publish, or preparation of the manuscript. The specific roles of all authors are articulated in the 'author	adenovirusvaccine carriers. Authors from Okairos were employees of and/or share holders in Okairos, this does not alter the authors' adherence to all the PLOS ONE policieson sharing data			
9	ipencer AJ	by fusion to MHC class ii invariant chain	2014 Plos One	contributions' section.	and materials.	N/A	N/A	16/12/20
S	Stedman A			This study was funded by the UK Department of Health and Social Care (UK DHSC, Project				
				16/107/03). G.M.W. is supported by an Oak foundation fellowship and aWellcome Trust grant (203077 Z 16 Z). S.C.G., B.C. and A.V.S.H. are JennerInvestigators. The funders had no role in				
				study design, data collection and analysis, decision to publish, or preparation of the manuscript.				
		Safety and efficacy of ChAdOx1 RVF		The views expressed in thispublication are those of the authors and do not necessarily reflect those of the UKDHSC. We thank Dr. Connie Schmaljohn (USAMRIID, Fort Detrick, MD) for				
		vaccine against Rift Valley fever in		providing the 4-D4 antibody. This paper is published with the permission of the PirbrightInstitute	S.C.G. and A.V.S.H. are co-founders of, consultants to and shareholders in VaccitechLtd., which is			
		pregnant sheep and goats	2019 Nature partner journals	and the Director of the Kenya Medical Research Institute.	developing ChAdOx1-vectored vaccines. The remaining authors declareno competing interests.	N/A	N/A	18/12/20
		An Ad/MVA vectored Theileria parva		This work was funded by the Bill and Melinda Gates Foundation (BMGF) and theDepartment for International Development (DFID) of the United Kingdom[OPP1078791], the Norman Borlaug				
		antigen induces schizont-specific CD8(+)		Commemorative Research Initiative, an initiativebetween the Feed the Future program of United				
		central memory T cells and confers		States Agency for International Development (USAID), USA and United States Department of				
,	ivitek N	partial protection against a lethal challenge	2018 Nature partner journals	Agriculture (USDA)-Agricultural Research Service, USA (58-5348-2-117F) and through funding from the CGIAR Research Program on Livestock and Fish [CRP 3.7]	N/A	N/A	N/A	18/12/20
				Funding:Supported by the Medical ResearchCouncil (MRC) UK and the European Union	Competing interests: S. Colloca, A.F., R.C., and A.N. are named inventors on patent applications		•	
		A human vaccine strategy based on chimpanzee adenoviral and MVA		(Framework VI; HEPACIVAC) for funding the studyand the manufacture of MVA-NSmut through an MRC UK DCS (Developmental Clinical Studies) award. E.B. is supported by the MRC as a Senior	covering HCV-vectored vaccines and chimpanzeeadenovirus vectors [WO 2006133911 (A3) hepatitis C virus nucleic acid vaccine, WO 2005071093(A3) chimpanzee adenovirus vaccine carriers,			
		vectors that primes, boosts, and sustains		Clinical Fellow, the Oxford Martin Schools, and National Institute for Health Research Oxford	WO 03031588 (A2) hepatitis C virus vaccine). P.K. hasacted as a consultant to Tibotec and Pfizer on			
S	Swadling L		2014 Science Transitional Medicine	Biomedical Research Centre. L. Swadling is supported by an MRC CASE studentship.	antiviral therapy. The other authors declare thatthey have no competing interests	N/A	N/A	16/12/20
				Supported by the Medical Research Council (MRC) UK and the European Union (FrameworkVI; HEPACIVAC) for funding the study and the manufacture of MVA-NSmut through an MRC UK				
				DCS(Developmental Clinical Studies) award (G0701694). Christabel Kelly and Paul Klenerman are	Stefano Colloca, Antonella Folgori, Riccardo Cortese and Alfredo Nicosia are namedinventors on			
				supported by the Wellcome Trust, the Oxford NHIR BRC and the U19 grant (2U19AI082630-06). Leo	patent applications covering HCV-vectored vaccines and chimpanzee adenovirus vectors[WO			
				Swadling is supported by an MRC CASE studentship. Elleanor Barnes is funded as an MRC Senior Clinical Fellow, and is supported by the Oxford NIHR BRC, the Oxford Martin School and the Jenner	2006133911 (A3) hepatitis C virus nucleic acid vaccine, WO 2005071093 (A3) chimpanzee adenovirusvaccine carriers, WO 03031588 (A2) hepatitis C virus vaccine]. Adrian Hill is a co-inventor			
S	Swadling L		2016 Vaccines	Institute.	on patent filings and applications related to heterologous prime-boost immunisations.	NCT01296451	N/A	20/12/2020
				This study was funded by a Wellcome Trust Strategic Translation Award, with funding contribution from the Medical Research Council UK, and the Department for International Development UK	s			
		Use of ChAd3-EBO-Z Ebola virus vaccine		from the Medical Research Council UK, and the Department for International Development UK supported the primary vaccination of 80 Malian participants with ChAd3-EBO-Z. A Wellcome Trust				
		in Malian and US adults, and boosting of		Enhancement Award funded the boosting of 52 Malians with MVA-BN-Filo or saline. Funding for				
		Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a		priming immunisation of the Malian participants with the ChAd3-EBO-Z vaccine and for data	FR, IDR, and WRB are employees of GlaxoSmithKline and manufacture non-replicating chimpanzee adenovirus 3-based vaccines. NS is a named inventor on patents related to ChAd3-EBO-Z. AVSH is			
		phase 1b, open-label and double-blind,		Cancer Research, Federal Funds from the National Institute of Allergy and Infectious Diseases, and	named as an inventor on patents using heterologous prime boost immunisation with viral vectors,			
		dose-escalation trial, and a nested,		a contract (number HHSN261200800001E) awarded to Leidos Biomedical Research. The US trial	such as those assessed in this report. MML serves as a member of the Scientific Advisory Working			
	Tapia MD	randomised, double-blind, placebo- controlled trial	2016 The Lancet Infectious Diseases	was funded by the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, through a contract to the EMMES Corporation.	Group to the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, and of the Vaccine Research Center Board of Scientific Counselors.	NCT02231866. NCT02267109	N/A	20/12/2020
	•							

This work was supported by an award from the European and Developing Countries Clinical Trials Partnership (EDCTP) and was performed by the Malaira' Vectored Vaccines Consortium (MVVC), a 5year integrated project (Grant number 12:00.8 3.110.00.11). The European Vaccine Initiative (EVI) was the coordinator of the EDCTP-funded MVVC project. Co-funding was also provided by the Swedsh internations.

Tiono AB	First field efficacy trial of the ChAdG3 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children		year mitegy are project, used in thimmen if JOAOS.3.1.00.001, in the European vectore instance (EVI) was the coordinatory of the EUTE-funded WINC project. Co-funding was also provided by the Swedish International Development Cooperation Agency (SIAD), the Austrian Federal Ministry of Science and Research, and rich Add. Additional support for the Oxford clinical trails seam was provided by the UK NINR through the Oxford Biomedical Research Centre	: AVSH is a named inventor on patent applications and issued patents relating to malaria vectored vaccines and immunization regimes. This does not alter the author's antenence to all the PLGS ONE policies on sharing data and materials. M. Tuffili. Ravison/Consultancy, Vaccitech Limited; Advisony/Consultancy, Speaker Bureau/Expert testimony: BMS, Advisony/Consultancy, Speaker Bureau/Expert testimony: Pleter-Advisony/Consultancy, Speaker Bureau/Expert testimony: Rovartis, Advisony/Consultancy, Speaker Bureau/Expert testimony: BMS, Advisony/Consultancy, Speaker Bureau/Expert testimony: Inscript testimony: January, Advisony/Consultancy, Speaker Bureau/Expert testimony: January, Ravisony/Consultancy, Speaker Bureau/Expert testimony: January, Basic Bureau/Expert testimony: January Advisony/Consultancy, Speaker Bureau/Expert testimony: January Advisory Consultancy, Speaker Bureau/Expert testimony: January Consultancy, Speaker Bureau/Expert testimony: January Consulta	NCT01635647. PACTR2012080000404131.	N/A	21/12/2020
Futhill M.	Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer	2020 Annals of Oncology (Abstracts)	European Union Seventh Framework Programme under grant AgreementNo. 602705 (Project IMPROVE) and Vaccitech Ltd.	testimony, Roche-Advisony/Consultancy, Lilly, Advisory/Consultancy, Dirdy Varmedix, Speaker Bureau/Expert testimony, Atabliss, Saeber Bureau/Expert testimony, Exemplis, Speaker Bureau/Expert testimony, Exemplis, Speaker Bureau/Expert testimony, Exemplis, Genetic, Travel/Accommodion/Expertises, LUSA Pharma, T. Furns: Laddeship role, Shareholder/Slockholder/Slock Options: Vacci-test Luimited. A Protheroe: Speaker Bureau/Expert testimony, BMS, A V.S. Hill: Advisory/Consultancy/Founder Vaccitesh: Vaccitesh Limited. All other authors have declared no conflicts of interval.	NCT03815942	N/A	18/12/20
	Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+T		This work was supported by grants AGL2017-82570-R from the Spanish Ministry of Science and EUHorizon 2020 Program (European Comission Grant Agreement NO.727393-PALE-Blu). SUT was a recipient of apredoctoral fellowship from the Instituto Nacional de Investigación y Tecnología				
Utrilla-Trigo S	Cell Immunity to Bluetongue Virus A single dose of ChAdOx1 MERS		Agraria y Alimentaria, Centro delinvestigación en Sanidad Animal (program FPF-SGT-201). This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), NIH (IZIAAU001179-01) and the Department of Health and Social Care using UK Aid funding managed by the NIHR.S.C.G. is a Jenner investigator. The views		N/A	N/A	18/12/20
van Doremalen N van Doremalen N	provides protective immunity in rhesus macaques A single-dose ChAdOx1-vectored vaccine provides complete protection against	2020 Science Advances	expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care. This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases(NIAID), National Institutes of Health(NIH). TAB issupported by the Medical	I have read the journal's policy and the authorsof this manuscript have the following competing	N/A	N/A	18/12/20
	Nipah Bangladesh and Malaysia in Syrian golden hamsters		Research Council (MR/L009528/1). SCG is a Jenner investigator. The sponsors did not play a role in study design.	interests:SCG is named as an inventor on a patent covering use of ChAdOx1-vectored vaccines. The remaining authors declare no conflict of interest.	N/A	N/A	18/12/20
van Doremalen N Werskatraman N	Ch4dOst nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus maraques	2020 Nature	This work was supported by the Intramural Research Program of the National Institute of Allergy and Infections Diseases (MAD), National Institutes of Health (NIH) (IZAA001179 01) and the Department of Health and Social Care value (IXA6 funding managed by the NIH. This work was supported by the Welkomer Trust, the UK Medical Research Council, the UK Department for International Development, and the UK NIHB ORDG Blomedical Research Centre. The Good Manufacturing Practice biomanifacture of MAV-EID-2 and the UK Cinital Trust was supported by an Enhancement Award to a Welkomer Trust Strategic Award (IO. A.V. S. H. as principal Investigation) co-funded by the Medical Research Council, the Department for International Development, and the European and Developing Countries Clinical Trusts	University nor Vaccitech will receive any royalities during the pandemic period or from any sales of the vaccine in developing countries. The other authors declare no competing interests. F. R. and W. R. B. are employ-ees of GSX and own restricted shares of the company. S. C. G., K. E.,	N/A	AZ in competing interests	18/12/20
	Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal Modeling Combinations of Pre-		Partnership (grant number 106235/2/14/A), with additional support from the NHR Oxford Biomedical Research Centre. The Sengell trial was ingredly funded by a European Commission Horizon 2020 program award Ebolalvac (www.ebolavac.eu; grant agreement 6666555), which provided additional resources for the MAV-EBO-2 biomanufacture. This study was also supported by Glasschillinia Biologicals SA. Andrew S. Waller, José Durenco and Sengel and Funded by the European Research Council	Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.		N/A	18/12/20
Walker AS Wang C	erythrocytic Plasmodium falciparum Malaria Vaccines	American Journal of Tropical 2015 Medicine and Hygiene	(ERCAdvanced Grant—Diversity). AVSH is a Jenner Investigator and Wellcome Trust and NIHR Senior Investigator.	N/A	N/A	N/A	20/12/2020
wang C	A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis		This work has been supported by the UK Medical Research Council including Confidence in Concept (grantsMC, PC_13073and MR/P017339/1). Slow Slow and ADD are lenner investigators; SD is also a sizer institute Research Prize Fellow and a Wellcome Trust Senior Fellow (grant105917/2/15/2). ADD is supported by the Wellcome Trust (grant1021477/2/16/2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ChAdOx2 vector. AVSH and SID are named inventors on a patent relating to the use of the intron- containing promoter used in ChAdOx2 RabG. The University Oxford and the Wistar Institute have entered into a partnership to share any future revenue from development of the ChAdOx2 RabG	N/A	N/A	21/12/2020
	Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against		This work was conducted with the support from the University of Oxford, a Wellcome Trust fellowship to GMW (WT098635) and grant from the Bill & Melinda Gates Foundation through the Grand Challenges Exploration Initiative to GMW (OPP1098893). B.C., S.C., G., and A.V.S.h. are Jenner				,,
Warimwe GM	Rift Valley Fever	2016 Scientific Reports	Investigators. This work was supported by a Wellcome Trust fellowship in PublicHealth and Tropical Medicine to GMW (grant no. 098635/8/12/Z) and by aSpanish Ministry of Science grant (no. AGI.2011-22485) to	N/A	N/A	N/A	20/12/2020
Warimwe GMLorenzo Foshida K	Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice	2013 Virology Journal	GMW (grant no. Usbes):y/L/// and by aspanish Ministry of Science grant (no. AsLzULI-2./465) to AR. ELG is a recipient of a pre-doctoral fellowship program from the Spanish Ministry of Science. SCG and AVSH are Jenner Investigators. This work was supported, in part, by a Grant-in-Aid for Young Scientists (B) (JSPS KAKENHI grant	vector (GB Patent application number 1108879.6).All other authors declare that they have no competing interests. The authors have read the journal's policy and declare the following conflicts of interest: 5.Y. and	N/A	N/A	16/12/20
	Adenovirus-prime and baculovirus- boost heterologous immunization achieves sterile protection against malaria sporzozite challenge in a murine		number 26860278), a grant from the Ohyama Health Foundation, and Cooperative Research Grants	s (WO/2007/091624) and ChAd63 (WO/2008/122769) anti-malaria vaccines, respectively. Neither of these products has been commercialized. None of the authors have undertaken any consultancies relevant to this study. These conflicts of interest do not alter the authors' adherence to all the			
	model		for challenging exploratory research (LSPS MAKENNI grant number 24059400) to 5.1.; and by the UN Medical Research Council (award number MR/N00227X/1) to A.M.B.		N/A	N/A	21/12/2020

A	Fundament	Awardee (to whom was the	D-4-	A	F	۸	ti- ODD	Relevant publications	Discret citation forms anticles
Award number	Funder name	grant?)	Date	Amount	Exchange rate	Ar	mount in GBP	(author and date)	Direct citation from articles
-	AIDS Vaccine Initiative	-	-	-				Borthwick et al (2014)	The work was supported by
BBS/E/I/00001373	Austrian Federal Ministry of Science and BBRSC	Bryan Charleston	- Jan 09 - Jan 13	£790,209		£	700 200 00	Tiono (2018)	This work was supported by a
BB/H010556/1	BBSRC	Tim Bull	Mar 10 - May 13	£351,371		£		Dicks et al (2015 - 2) Bull et al (2014)	This work has been funded by This work was supported by B
						£	,	· ·	• • • • • • • • • • • • • • • • • • • •
BB/H010718/1	BBSRC BBSRC	Jayne Hope Hope J	Sep 11 - Aug 13	£235,928		£	235,928.00	Bull et al (2014)	This work was supported by B
-	BBSRC	McGuines I	-	-				Bull et al (2014) Bull et al (2014)	This work was supported by B This work was supported by B
LDAD P15820	BBSRC	-		_				Goodman et al (2011)	This work was supported by B
LDAD_P15820	BBSRC	_						Goodman et al (2011)	This work was supported prim
OPP1096893	Bill & Melinda Gates Foundation	Warimwe GM			1			Dulal et al (2016)	This study was conducted witl
OPP1096893	Bill & Melinda Gates Foundation	Warimwe GM	<u> </u>	I-	1	_			•
			- 0.110			70 6	7.040.045.20	Warimwe et al (2016)	This work was conducted with
OPP1078791	Bill and Melinda Gate Foundation	Research Institute		\$ 10,999,924			7,919,945.28		This work was funded by the I
OPP1215550	Bill and Melinda Gates Foundation	The Pirbright Institute	Nov-19	\$ 5,530,900	0	./2 £	3,982,248.00	S Graham (2020)	and the Bill and Melinda Gate
3436	Bill and Melinda Gates Foundation	-	-	-				Pearson et al (2013)	This work has been supported
-	Biotechnology and Biological Sciences R		-	-				Boyd et al (2013)	The Biotechnology and Biolog
-	Bundesministerium für Bildung und Fors		-	-				Mensah (2017)	This work was supported by a
-	Cancer Research	Malinauskas T	-	-				Bauza et al (2014)	The work was funded by a W ϵ
-		Jones EY	-	-				Bauza et al (2014)	The work was funded by a W ϵ
-	CAPES	Atcheson E		-				Atcheson (2018)	The work was funded by a Wε
CRP 3.7	CGIAR Research Program on Livestock as	-	-	-				Svitek (2018)	This work was funded by the I
-	Coalition for Epidemic Preparedness Inne	-	-	-				Folegatti P.M.(2020)	UK Department of Health and
finance code 001	Coordenacao de Aperfeicoamento de Pe	· ·	-	-				Folegatti P.M.(2020)	UK Department of Health and
finance code 001	Coordenacao de Aperfeicoamento de Pe	-	-	-				Folegatti P.M.(2020)	UK Department of Health and
-	Dakar University Cheikh Anta Diop	-	-	-				Mensah et al (2016)	This study was supported by a
-	Danida	-	-	-				Payne et al (2017)	This work was supported by fu
	Department for Business, Energy and Inc			£65,500,000.00			65,500,000.00		uk/news/197573/covid-19-vacc
	Department for Business, Energy and Inc	= -		£20,000,000.00		£	20,000,000.00		uk/news/197017/imperial-covic
-	Department for International Developme		-	-				Bowyer (2018)	The clinical trial was supporte
-	Department for International Developme		-	-				Venkatraman N (2019)	This work was supported
-	Department of Biotechnology, Governme		-	-				de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
-	Department of Biotechnology, Government		-	-				de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
-	Department of Foreign Affairs and Trade	-	-	-				Mensah (2017)	This work was supported by a
-	DFID	-	-	-				Tapia et al (2016)	This study was funded by a W
-	DFID	-	-	-				Ewer et al (2016)	Supported by the Wellcome T
-	Division of Intramural Research	-	-	-				Forbes et al (2012)	This work was funded by the \
-	Dr. Saal van Zwanenberg Stichting	van Laarhoven A	-	-				Lambe et al (2013)	AvL was funded by a fellowsh
IP.2008.31100.00	EDCTP	-	-	-				Kimani et al (2014)	This work was supported by
IP.2008.31100.001	EDCTP	-	-	-				Afolabi et al (2016)	Trials Partnership (EDCTP) and
IP.2008.31100.001	EDCTP	-	-	-				Mensah et al (2016)	This study was supported by a
IP.2008.31100.001	EDCTP	-	-	-				Nébié et al (2014)	This work was supported by a
-	EMVDA	Dicks MDJ	-	-				Dicks et al (2012)	This work has been funded by
-	EMVDA	Dicks MDJ	-	-				Dicks et al (2015 - 2)	This work has been funded by
-	EMVDA	-	-	-				Forbes et al (2012)	This work was funded by the \
LSHP-CT-2007-03750	EMVDA	-	-	-				Biswas et al (2014)	This work was supported by th
LSHP-CT-2007-037506		-		-				Sheehy et al (2011)	This work was supported by the
LSHP-CT-2007-037506		-	-	-				Sheehy et al (2012 - 2)	This work was supported by th
LSHP-CT-2007-037506	EMVDA	-	-	-				Sheehy et al (2012)	This work was supported by
LSHP-CT-									
2007-037506	EMVDA	-	-	-				Hodgson et al (2014)	This work was supported by th
	EMVDA		-	-				Draper et al (2011)	SB was funded by MalParTraii

EP/R013756/1 CFTD07/117 CFTD07/117 IP.2008.31100.001 SP.2011.41304.025 IP.2008.31100.001	Engineering and Physical Sciences Resea Enterprise Ireland Enterprise Ireland EU HEPACIVAC European and Developing Countries Clini European and Developing Countries Clini	-	Apr 18 - Sep 21	£6,968,179	£	6,968,179.00	Folegatti P.M.(2020) Pearson et al (2015) Carey et al (2013) Swadling (2016) Bowyer G (2020) Reyes-Sandoval (2010) Bowyer (2018) Venkatraman N (2019) Ogwang et al (2015) Mensah (2017) Tiono (2018)	UK Department of Health and This study was funded by Ente This work wassupported by Er Supported by the Medical Res The Oxford clinical trial was s Work in the Oxford malaria va The clinical trial was supported This work was supported This work was funded by the E This work was supported by a This work was supported by a
66608	5 European Comission	BIOLOGICALS SA	07-Oct-14	€ 15,153,216	0.87 £	13,183,297.92	Venkatraman N (2019)	This work was supported
		GLAXOSMITHKLINE						
	5 European Commission	BIOLOGICALS SA	07-Oct-14	€ 15,153,216			Bowyer G (2020)	The Oxford clinical trial was s
24209	5 European Commission	Salman AM	01-Oct-09	€ 12,000,000	0.87 £	10,440,000.00	Atcheson (2018)	The work was funded by a W€
		THE UNIVERSITY OF						
727393-PALE-Blu	European Commission	NOTTINGHAM	01-Jun-17	€ 6,039,301.50	0.87 £		Utrilla-Trigo S (2020)	This work was supported by g
60270	5 European Commission	-	-	€ 6,000,000	0.87 £	5,220,000.00	Cappuccini F (2020)	The VANCE clinical trial was s
		THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF						
	5 European Commission	OXFORD	01-Apr-14	€ 6,000,000	0.87 £		Tuthill M. (2020)	European Union Seventh Fram
31665	5 European Commission	Halbroth BR	01-Nov-12	€ 3,060,467.67	0.87 £	2,662,606.87	Halbroth (2018)	BRH received funding from th
31665	5 European Commission	Halbroth BR					Gola (2018)	A.G. is funded by the Wellcom
-	European Commission	-					Reyes-Sandoval (2010)	Work in the Oxford malaria va
IC18-CT95-0019	European Commission	Fellowship to author to J.S.					Gilbert et al (2002)	Wellcome Trust and the Eu
21241	4 European Community's 7th Framework	UNIVERSIDAD COMPLUTENS	01-Oct-08	€ 2,894,759	0.87 £	2,518,440.33	Pérez et al (2013)	The study was funded by th
24209	5 European Community's Seventh Framev	Janse CJ					Longley et al (2015)	This work has been funded by
24209	5 European Community's Seventh Framev	ı –	-	€ 12,000,000	0.87 £	10,440,000.00	Forbes et al (2012)	This work was funded by the \
-	European Malaria Vaccine Development	-					Draper et al (2010)	This work was funded by the \
LSHP-CT-2007-03750	6 European Malaria Vaccine Development	-					Elias et al (2013)	This work was supported by th
LSHP-CT-2007-03750	6 European Malaria Vaccine Development	de Cassan SC					Payne (2017)	This work was supported by a
LSHP-CT-2007-03750	6 European Malaria Vaccine Development	de Cassan SC	- -				de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supp
-	European Malaria Vaccine Devlopment	!-					Capone et al (2010)	This work was supported by th
-	European Malaria Vaccine Initiative	-					Reyes-Sandoval (2010)	Work in the Oxford malaria va
-	European Research Council	Walker A					Walker et al (2015)	Andrew S. Walker, José Loure
-	European Research Council	Lourenço J					Walker et al (2015)	Andrew S. Walker, José Loure
-	European Research Council	Gupta S					Walker et al (2015)	Andrew S. Walker, José Loure
30528	2 European Union	MultiMalVax	01-Oct-12	€ 6,000,000	0.87 £	5,220,000.00	Payne et al (2017)	This work was supported by fu
	5 European Union	Halbroth BR					Longley et al (2017)	Funding for manufacture and
	5 European Union	Capuccini F					Capuccini et al (2017)	This work was supported by O
60270	5 European Union	Pollock E					Capuccini et al (2017)	This work was supported by O
Framework VI;HEPAC	:IV European union	-					Barnes et al (2012)	European Union (Framework
	5 European Union's Seventh Framework P	Capuccini F	01-Apr-14	€ 6,000,000	0.87 £	5,220,000.00	Capuccini et al (2016)	This work was supported by O
	5 European Union's Seventh Framework P	•	-			•	Capuccini et al (2016)	This work was supported by O
-	European Vaccine Initiative	-					Cottingham et al (2012)	This work was supported by th
-	European Vaccine Initiative	-					de Barra et al (2014)	The study was funded by a gra
-	European Vaccine Initiative	Chauhan VS					de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supp
-	European Vaccine Initiative	Chitnis CE					de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
-	European Vaccine Initiative	Viebig NK					Kimani et al (2014)	This work was supported by
24209	5 EVIMalaR	-					Biswas et al (2014)	This work was supported by th

242005	EV/IMA-ID			
	EVIMalaR EVIMalaR	-	-	-
	EVIMAIAR	Salman M	<u>-</u> -	-
	EVIMalaR	Jaiman IVI	-	
242095		-	-	-
-		Salman AM	-	-
-	Foundation to NIH	Hill A.V.S	-	-
-	Frederick National Laboratory for Cancer	-	-	-
-	Gates Foundation	-	-	-
-	Gates Foundation (through the foundation	-	-	-
-	German Center for Infection Research	-	-	-
-	Graduate Women in Science	Coughlan L	-	-
-	Grand Challenges in Global Health	-	-	-
24659460	Grant-in-Aid for Challenging Exploratory	Yoshida S	-	_
	Grant-in-Aid for Young Scientists	-	-	-
	Grants-in-Aid for Scientific Research	-	_	_
	Grants-in-Aid for Scientific Research	_	-	-
_	GSK	_		_
_	HAV Vaccines Ltd	_	_	_
-	HEPACIVAC	-	-	-
LSH-2005-1.2.4-2 proje	•	-	-	-
-	Imperial College NIHR Wellcome Trust C	-	-	-
971510	Innovate UK	The Jenner Institute, University	Apr 17 - May 18	£483,455
FPI-SGIT-201	Instituto Nacional de Investigación y Tec	Utrilla-Trigo S	-	-
-	Irish Aid	-	-	-
-	Irish Aid	-	-	-
_	Irish Aid	_	_	_
	Irish Aid			
-		-	-	-
-	James Martin School for 21st Century, O		-	-
-	Jenner Institue	Gilbert SC	-	-
-	Jenner Institue	Hill AVS	-	-
-	Jenner Institue	Hill AVS	-	-
-	Jenner Institue	Gilbert SC	-	-
-	Jenner Institute	Reyes-Sandoval A	-	-
_	Jenner Institute	Hill A.V.S	-	-
_	Jenner Institute	Hill AVS	-	-
_	Jenner Institute	Reyes-Sandoval A	-	-
_	Jenner Institute	McShane H	-	_
_	Jenner Institute	Hill AVS	-	-
_	Jenner Institute	Reyes-Sandoval A	-	-
_		Hill AVS	_	_
_	Jenner Institute	Draper SJ	_	_
_		Hill AVS	_	_
	Jenner Institute	Gilbert SC	_	_
	Jenner Institute	Hill AVS		_
-	Jenner Institute	Gilbert SC	-	-
-			-	-
-		Hill AVS	-	-
-	Jenner Institute	Draper SJ	-	-
-	Jenner Institute	Gilbert SC	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Gilbert SC	-	-
-	Jenner Institute	Gilbert SC	-	-
-	Jenner Institute	Hill A.V.S.	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Charleston B	-	-

		Elias et al (2013) Hodgson et al (2014) Salman et al (2017) Sheehy et al (2012) Longley et al (2015)	This work was supported by the This work was supported by the The work was funded by a We This work was supported by This work has been funded by
		Halbroth (2018)	BRH received funding from th
		Tapia et al (2016)	This study was funded by a W
		Reyes-Sandoval (2010)	Work in the Oxford malaria va
		Cottingham et al (2012)	This work was supported by th
		Folegatti P.M.(2020)	UK Department of Health and
		Bliss (2020)	This research project was sup
		•	We thank the Jenner Institu
		Yoshida Klyori (2018)	This work was supported, in p
		Yoshida Klyori (2018)	This work was supported, in p
		Yoshida Klyori (2018) Yoshida Klyori (2018)	This work was supported, in p This work was supported, in p
		Venkatraman N (2019)	This work was supported
		Folegatti P.M. (2019)	This research was funded by F
		Swadling et al (2014)	Funding:Supported by the Me
		Colloca et al (2012)	This work was supported in pa
		Rampling et al (2016)	This work was supported by th
£	483,455.00	Sebastian S (2020)	This research was funded by I
		Utrilla-Trigo S (2020)	This work was supported by g
		Afolabi et al (2016)	Trials Partnership (EDCTP) and
		Mensah (2017)	This work was supported by a
		Mensah et al (2016)	This study was supported by a
		Tiono (2018)	This work was supported by a
		Barnes et al (2012)	European Union (Framework '
		de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supp
		Dicks et al (2012)	This work has been funded by
		Sheehy et al (2012)	This work was supported by
		Sheehy et al (2012) Atcheson (2018)	This work was supported by The work was funded by a We
		Atcheson (2018)	The work was funded by a We
		Bauza et al (2014)	The work was funded by a We
		Bauza et al (2014)	The work was funded by a Wε
		Betts et al (2012)	Funding was provided by NEW
		Betts et al (2012)	Funding was provided by NEW
		Betts et al (2012)	Funding was provided by NEW
		Biswas et al (2014) Biswas et al (2014)	This work was supported by the This work was supported by the
		Carey et al (2013)	This work was supported by Er
		Carey et al (2013)	This work wassupported by Er
		de Barra et al (2014)	The study was funded by a gra
		de Barra et al (2014)	The study was funded by a gra
		de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supp
		de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supp
		Dicks et al (2012)	This work has been funded by
		Dicks et al (2015) Dicks et al (2015)	This work has been funded by This work has been funded by
		Draper et al (2010)	This work has been runded by This work was funded by the \
		Draper et al (2010)	This work was funded by the \
		Dulal et al (2016)	This study was conducted witl
		Dulal et al (2016)	This study was conducted witl

_	Jenner Institute	Hill AVS	_	_
_	Jenner Institute	Draper SJ	_	_
_	Jenner Institute	Hill AVS	-	-
_	Jenner Institute	Draper SJ	_	_
_	Jenner Institute	Gilbert SC	_	_
	Jenner Institute	Reyes-Sandoval A		
-		•	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Draper SJ	-	-
-	Jenner Institute	Draper SJ	-	-
-	Jenner Institute	Hill A.V.S	-	-
-	Jenner Institute	Barnes E	-	-
-	Jenner Institute	Gilbert SC	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Hill A.V.S	-	-
-	Jenner Institute	Draper SJ	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Draper SJ	-	-
-	Jenner Institute	Biswas S	-	-
-	Jenner Institute	Reyes-Sandoval A	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Gilbert SC	-	-
_	Jenner Institute	Hill AVS	_	_
_	Jenner Institute	Draper SJ	_	_
_	Jenner Institute	Gilbert SC	_	-
_	Jenner Institute	Draper SJ	_	_
_	Jenner Institute	Draper SJ	_	_
_	Jenner Institute	Gilbert S.C.	_	_
_	Jenner Institute	Charleston B	_	_
_	Jenner Institute	A.V.S Hill	_	_
_	Jenner Institute	Barnes E		_
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Hill A.V.S	-	-
-			-	-
-	Jenner Institute	Draper AD	-	-
-	Jenner Institute	Douglas SJ	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Gilbert SC	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Gilbert SC	-	-
-	Jenner Institute	Charleston B	-	-
-	Jenner Institute	Hill AVS	-	-
-	Jenner Institute	Gilbert S.C.	-	-
-	Jenner Institute	Douglas AD	-	-
-	Jenner Institute	Rollier C	-	-
-	Jenner Institute	Hill A.V.S.	-	-
-	Jenner Institute	Gilbert S.C.	-	-
-	Jenner Institute	Gilbert S.C.	-	-
-	Jenner Vaccine Foundation	-	-	-
RC16/093	KAIMRC	Naif Khalaf Alharbi	-	-
HI15C2971	Korean Ministry of Health and Welfare	-	-	-
-	Lister Institute	Draper SJ	-	-
-	Lister Institute	Draper SJ	-	-
-	Lister Institute	Draper SJ	-	-
-	Lister Institute	Draper SJ	-	-
-	Lister Institute	Draper SJ	-	-

Elias et al (2013)	This work was supported by th
Elias et al (2013)	This work was supported by th
Ewer et al (2013)	The study was funded by gran
Ewer et al (2013)	The study was funded by gran
Ewer et al (2013)	The study was funded by gran
Ewer et al (2013)	The study was funded by gran
Forbes et al (2012)	This work was funded by the \
Forbes et al (2012)	This work was funded by the \
Goodman et al (2011)	This work was supported prim
Goodman et al (2011)	This work was supported prim
Kelly et al (2016)	Supported by a Medical Resea
Lambe et al (2013)	AvL was funded by a fellowsh
Longley et al (2015)	This work has been funded by
Longley et al (2017)	Funding for manufacture and
Payne (2017)	This work was supported by a
Payne (2017)	This work was supported by a
Payne et al (2017)	This work was supported by fu
Payne et al (2017)	This work was supported by fu
Payne et al (2017)	This work was supported by fu
Salman et al (2017)	The work was funded by a We
Salman et al (2017)	The work was funded by a W€
Sheehy et al (2011)	This work was supported by th
Sheehy et al (2011)	This work was supported by th
Sheehy et al (2011)	This work was supported by th
Sheehy et al (2012 - 2)	This work was supported by th
Sheehy et al (2012 - 2)	This work was supported by th
Sheehy et al (2012)	This work was supported by
Stedman (2019)	This study was funded by the
Stedman (2019)	This study was funded by the
Stedman (2019)	This study was funded by the
Swadling (2016)	Supported by the Medical Res
Walker et al (2015)	Andrew S. Walker, José Loure
Wang (2018)	This work has been supported
Wang (2018)	This work has been supported
Wang (2018)	This work has been supported
Warimwe et al (2013)	This work was supported by a
Warimwe et al (2013)	This work was supported by a
Warimwe et al (2016)	This work was conducted with
Warimwe et al (2016)	This work was conducted with
Warimwe et al (2016)	This work was conducted with
Sheehy et al (2012 - 2)	This work was supported by th
Alharbi (2019)	This study is funded by KAIMR
Fedosyuk S (2019)	This work was supported by N
Rollier C (2020)	This work was funded by a gra
Rollier C (2020)	This work was funded by a gra
Rollier C (2020)	This work was funded by a gra
van Doremalen N (2019)	This work was supported by th
Reyes-Sandoval (2010)	Work in the Oxford malaria va
Alharbi (2019)	This study is funded by KAIMR
Folegatti P.M.(2020)	UK Department of Health and
Biswas et al (2014)	This work was supported by th
Elias et al (2013)	This work was supported by the
Payne (2017)	This work was supported by a
Payne et al (2017)	This work was supported by fu
Carey et al (2013)	This work wassupported by Er

-	Lister Institute Malaria Vaccine Initiative	Douglas SJ	-	-			Wang (2018) de Barra et al (2014)	This work has been supported The study was funded by a gra
-	Malaria Vaccine ilitiative Malaria Vectored Vaccines Consortium	- (-	-	-			Ogwang et al (2015)	This work was funded by the I
MEST-CT-2005-	Maiaria Vectorea Vaccines consortiani	1					ogwang et al (2013)	This work was randed by the t
020492	MalParTraining	Biswas S	_	-			Draper et al (2011)	SB was funded by MalParTrain
G0600424	Medical Research Council	Anna Louise Goodman	Sep 06 - Oct 09	£159,968	£	159,968.00	Goodman et al (2011)	This work was supported prim
-	Meningitis UK	Rollier CS	-	-	-	133,300.00		0 We thank the Jenner Institu
-	Merck KGaA	-	_	-			Fedosyuk S (2019)	This work was supported by N
-	Merton College, Oxford	Draper SJ	-	-			Draper et al (2010)	This work was funded by the \
-	Merton College, Oxford	Draper SJ	-	-			Draper et al (2011)	SB was funded by MalParTrain
-	MEWA, Saudi Arabia	-	-	-			Alharbi (2019)	This study is funded by KAIMR
-	MRC	-	-	-	-		Bowyer (2018)	The clinical trial was supporte
-	MRC	-	-	-	-		Coughlan L (2018)	Medical Research Council UK,
-	MRC	Juthathip Mongkolsapaya	-	-	-		Lopez-Camacho (2018)	This report is independent res
-	MRC	-	-	-	-		Mensah (2017)	This work was supported by a
-	MRC	Warimwe GM	-	-	-		Munster (2017)	This work is published withthe
-	MRC	-	-	-	-		Venkatraman N (2019)	This work was supported
MC_UU_12014	MRC	Patel AH, Kohl A	-	<u>-</u>	-		Lopez-Camacho (2018)	This report is independent res
MR/P017339/1	MRC	Alexander Donald Douglas	Apr 17 - Mar 22	£2,228,194	£	2,228,194.00	Fedosyuk S (2019)	This work was supported by N
MR/P017339/1	MRC	Alexander Donald Douglas	Apr 17 - Mar 22	£2,228,194	£	2,228,194.00	Wang (2018)	This work has been supported
MR/N019008/1	MRC	Reyes-Sandoval A	Aug 16 - Feb 22	£1,792,688	£	1,792,688.00	Atcheson (2018)	The work was funded by a We
MR/N019008/1	MRC	Reyes-Sandoval A	Aug 16 - Feb 22	£1,792,688	£	1,792,688.00	Salman et al (2017)	The work was funded by a We
G0701669	MRC	Tomas Hanke	Oct 08 - Oct 12	£1,300,519	£	1,300,519.00	Borthwick et al (2014)	The work was supported by
MR/L009528/1	MRC	Thomas Alexander Bowden	Jan 14 - Dec 18	£1,144,287	£	1,144,287.00	van Doremalen N (2019)	This work was supported by th
G1000527	MRC	Draper SJ	Aug 10 - Jul 15	£1,104,645	£	1,104,645.00	Biswas et al (2014)	This work was supported by th
G1000527	MRC	Draper SJ	Aug 10 - Jul 15	£1,104,645	£	1,104,645.00	Carey et al (2013)	This work wassupported by Er
G1000527	MRC	Draper SJ	Aug 10 - Jul 15	£1,104,645	£	1,104,645.00	Elias et al (2013)	This work was supported by th
G1000527	MRC	Draper SJ	Aug 10 - Jul 15	£1,104,645	£	1,104,645.00	Sheehy et al (2012 - 2)	This work was supported by th
G1100086	MRC	Simon Draper	Jul 11 - Jun 14	£895,438	£	895,438.00	Payne (2017)	This work was supported by a
G0700735	MRC	Adrian Hill	Jan 08 - Dec 10	£748,840	£	748,840.00	Biswas et al (2014)	This work was supported by th
G0700735	MRC	Adrian Hill	Jan 08 - Dec 10	£748,840	£	748,840.00	Elias et al (2013)	This work was supported by th
MR/N006372/1	MRC	Sarah Catherine Gilbert	Mar 16 - May 18	£679,559	£	679,559.00	Asthagiri Arunkumar (201	9 The study was fundedby an M
MC_PC_13073	MRC	Chas Bountra	Mar 14 - Sep 15	£650,000	£	650,000.00	Wang (2018)	This work has been supported
G0502018	MRC	Adrian Hill	Oct 06 - Jan 09	£647,586	£	647,586.00	O'Hara et al (2012)	Financial support. This work w
		Andrew Michael						This work was supported, in p
MR/N00227X/1	MRC	Blagborough	Jan 16 - Apr 19	£549,297	£	549.297.00	Yoshida Klyori (2018)	
MC_PC_15040	MRC	Stephen Ward	Mar 16 - Feb 18	£500,000	£		Sebastian S (2020)	This research was funded by I
G0701694	MRC	Eleanor Barnes	Aug 09 - Jul 12	£250,000	£		Kelly et al (2016)	Supported by a Medical Resea
G0701694	MRC	Eleanor Barnes	Aug 09 - Jul 12	£250,000	£		Swadling (2016)	Supported by the Medical Res
MR/N017552/1	MRC	Kohl A	Jan 16 - Jan 19	£221,947	£		Lopez-Camacho (2018)	This report is independent res
G0600424	MRC	SJD	-	-	£		Goodman et al (2011)	This work was supported prim
G0600424	MRC	Goodman A	Sep 06 - Oct 09	£159,968	£		Ewer et al (2013)	The study was funded by gran
-	MRC	-	-	-			Afolabi et al (2016)	Trials Partnership (EDCTP) and
-	MRC	-	-	-			Antrobus et al (2014)	The study was funded by gran
-	MRC	-	-	-			Barnes et al (2012)	European Union (Framework
-	MRC	Jones EY	-	-			Bauza et al (2014)	The work was funded by a Wε
-	MRC	Malinauskas T	-	-			Bauza et al (2014)	The work was funded by a Wε
-	MRC	-	-	-			Bowyer G (2020)	The Oxford clinical trial was s
-	MRC	Stribbling S	-	-			Capuccini et al (2016)	This work was supported by O
-	MRC	Stribbling S	-	-			Capuccini et al (2017)	This work was supported by O
-	MRC	Bartiromo M	-	-			Colloca et al (2012)	This work was supported in pa
-	MRC	-	-	-			Ewer et al (2013)	The study was funded by gran
-	MRC	Draper SJ	-	-			Forbes et al (2012)	This work was funded by the \

-	MRC	Draper SJ	-	-			Goodman et al (2011)	This work was supported prim
-	MRC	Goodman AL	-	-			Goodman et al (2011)	This work was supported prim
-	MRC	Barnes E	-	-			Kelly et al (2016)	Supported by a Medical Resea
-	MRC	-	-	-			Kimani et al (2014)	This work was supported by
-	MRC	-	-	-			Mensah et al (2016)	This study was supported by a
-	MRC	-	-	-			Ogwang et al (2013)	This work was performed by t
-	MRC	-	-	-			Swadling (2016)	Supported by the Medical Res
_		Swadling L	-	-			Swadling (2016)	Supported by the Medical Res
_		Barnes E	-	_			Swadling (2016)	Supported by the Medical Res
_	MRC	-	-	_			Swadling et al (2014)	Funding:Supported by the Mei
_		Barnes E	-	_			Swadling et al (2014)	Funding:Supported by the Mei
_		Swadling L	_	_			Swadling et al (2014)	Funding:Supported by the Mei
_	MRC	-	_	_			Tapia et al (2016)	This study was funded by a W
_	MRC	_	_	_			Ewer et al (2016)	Supported by the Wellcome T
_		Swadling L	_	_			Kelly et al (2016)	Supported by a Medical Resea
G0600311	MRC	Swaamig E					Pearson et al (2013)	
		-	-	-			·	This work has been supported
G0600311	MRC	-	-	-			Pearson et al (2015)	This study was funded by Ente
G0600424		ALG	Sep 06 - Oct 09	£159,968			Goodman et al (2011)	This work was supported prim
G0700735	MRC	=	-	-			Sheehy et al (2011)	This work was supported by th
G1000157	MRC	Draper SJ	-	-			Sheehy et al (2011)	This work was supported by th
G1000527	MRC	Draper SJ	-	-			de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
MR/K017632/1)	MRC	Alanine DGW	-	-			Payne et al (2017)	This work was supported by fu
U117532067	MRC	Holder AA	-	-			Draper et al (2011)	SB was funded by MalParTrain
-	MRC and DFID	-	-	=			Afolabi et al (2016)	Trials Partnership (EDCTP) and
_	MRC and DFID	-	-	-			Afolabi et al (2016)	Trials Partnership (EDCTP) and
_		Bejon P	_	_			Ogwang et al (2015)	This work was funded by the I
_	National Cancer Institute	-	_	_			Tapia et al (2016)	This study was funded by a W
P51 RR000167	National Center for Research Resources	_	_	_			Rollier C (2020)	This work was funded by a gra
RR020141	National Center for Research Resources			_			Rollier C (2020)	This work was funded by a gra
RR15459	National Center for Research Resources			_			Rollier C (2020)	This work was funded by a gra
P51 RR000167	National Centre for Research Resources		-	-			Spencer et al (2014)	This work has been funded by
RR020141	National Centre for Research Resources		-	-			Spencer et al (2014)	This work has been funded by
RR15459	National Centre for Research Resources		-	-			Spencer et al (2014)	This work has been funded by
NN 13439	National Health Service Blood and Trans		-	-				
-			-	-			Ewer et al (2016)	Supported by the Wellcome T
-	National Institute of Health and Research		-	-			Tiono (2018)	This work was supported by a
-	National Institute of Allergy and Infection		-	-			Sheehy et al (2012 - 2)	This work was supported by the
-	National Institute for Health and Resear	=	-	-			Barnes et al (2012)	European Union (Framework
-	National Institute for Health Research	-	- 1	-			Bowyer G (2020)	The Oxford clinical trial was s
-	National Institute for Health Research	-]-	-			de Cassan et al (2011)	S.C.d.C. is a Ph.D. student sup
-	National Institute for Health Research	-	-	-			Folegatti P.M.(2020)	UK Department of Health and
-		Rollier C	-	-			Rollier C (2020)	This work was funded by a gra
-		Hill A.V.S.	-	-			Rollier C (2020)	This work was funded by a gra
-	National Institute for Health Research		-	-			van Doremalen N (2020)	This work was supported by the
-	National Institute for Health Research		-	-			van Doremalen N (2020)	This work was supported by the
-	National Institute of Allergy and Infectio		-	-			Sheehy et al (2012)	This work was supported by
HHSN272201400008C	National Institute of Allergy and Infectio		09/01/2014	\$78,100,000	0.72	£ 56,232,000.00	S Graham (2020)	Development of SARS-CoV-2 r
-	National Institute of Allergy and Infectio		-	-	_		Biswas et al (2014)	This work was supported by th
-	National Institute of Allergy and Infection		-	-			Sheehy et al (2011)	This work was supported by th
-	National Institute of Allergy and Infectio		-	-			Tapia et al (2016)	This study was funded by a W
-	National Institute of Allergy and Infectio		-	-			Tapia et al (2016)	This study was funded by a W
HHSN261200800001E	0,		-	-			Tapia et al (2016)	This study was funded by a W
R44AI058375	National Institute of Allergy and Infectio	-	-	-			Longley et al (2017)	Funding for manufacture and
	National Institute of Allergy and							
	Infectious Diseases		-	-			Draper et al (2011)	SB was funded by MalParTrain
								•

	National Institute of Allergy and Infection			
	National Institute of Allergy and Infection		-	-
	National Institute of Allergy and Infection		-	-
-	National Institute of Allergy and Infectio		-	-
-	National Institute of Allergy and Infection		-	-
HHSN2/2201400008C	National Institute of Allergy and Infection) -	-	-
-	National Institute of Health	-	-	-
-	National Institute of Health	-	-	-
-	National Institute of Health	Hill A.V.S	-	-
-	National Institute of Health	-	-	-
-	National Institute of Health National Institute of Health	-	-	-
-		-	-	-
-	National Institute of Health	-	-	-
HHSN272201400008C	National Institute of Health	-	-	-
	National Institute of Health		-	-
HILL05GCGH0	National Institute of Health		-	-
-	National Institute of Health and Research	; -	-	-
-	National Institute of Health and Research	: -	-	-
-	National Institute of Health and Research	: -	-	-
-	National Institute of Health and Research	:-	-	-
-	National Institutes of Allergy and Infecti	ı –	-	-
1ZIAAI001179-01	National Institutes of Health	MUNSTER, VINCENT	2013	\$877,861
-	National Institutes of Health	-	-	-
-	National Institutes of Health	-	-	-
-	National Institutes of Health, National II	· -	-	-
-	NDM	Biswas S	-	-
26-6.	NEKKEN	lyori M	2014	_
27-5.	NEKKEN	lyori M	2015	
EC FP7	NEWTBVAC	-	_	_
1041802		McCarthy JS	_	_
10418020		•		
		McCarthey JS	-	- 4522.004
5T32Al007647-17	NIAID	PALESE, PETER	04-May-16	
1R03AI142046-01	NIAID	ALBRECHT, RANDY A.	01-Dec-18	\$84,750
-	NIAID	Gola A	-	-
-	NIAID	Uderhardt S	-	-
-	NIAID	Germain RN	-	-
-	NIAID	-	-	-
AI109946	NIAID	-	-	-
HHSN272201400008C	NIAID	-	-	-
HHSN272201400008C	NIAID	-	-	-
1U19AI082630-01	NIH	CHUNG, RAYMOND T	07-Jun-09	\$3,086,377
2U19AI082630-06	NIH	CHUNG, RAYMOND T	30-May-14	
-	NIH	-	-	-
2U19AI082630-06	NIH	Klenerman P		
	NIH		-	-
2U19Al082630-06		Kelly C	-	-
2U19AI082630-06	NIH	Klenerman P	-	-
HILL05GCGH0	NIH	-	-	-
-	NIH foundation	-	-	-
-	NIHR	-	-	-
-	NIHR		-	-
-	NIHR	Hill AVS	-	-
-	NIHR	Hill AVS	-	-
-	NIHR		-	-
-	NIHR (Oxford Biomedical Research Cent	-	-	-

		Dayma at al /2017)	This work was supported by fi
		Payne et al (2017) van Doremalen N (2019)	This work was supported by fi This work was supported by the
		van Doremalen N (2020)	This work was supported by the
		van Doremalen N (2020)	This work was supported by the
		van Doremalen N (2020)	This work was supported by the
		Biswas et al (2014)	This work was supported by the
		Folegatti P.M. (2019)	This research was funded by F
		Gola (2018)	A.G. is funded by the Wellcom
		Reyes-Sandoval (2010)	Work in the Oxford malaria va
		Rollier C (2020)	This work was funded by a gra
		Sheehy et al (2012)	This work was supported by
		Sheehy et al (2012 - 2)	This work was supported by th
		Bliss (2020)	This research project was sup
		Draper et al (2011)	SB was funded by MalParTrain
		Spencer et al (2014)	This work has been funded by
		Bowyer (2018)	The clinical trial was supporte
		Coughlan L (2018)	Medical Research Council UK,
		Venkatraman N (2019)	This work was supported
		Bliss (2018)	This study was funded by the
0.70 6	622.050.02	Forbes et al (2012)	This work was funded by the \
0.72 £	632,059.92	van Doremalen N (2020)	This work was supported by the
		Forbes et al (2012) Sheehy et al (2011)	This work was funded by the \ This work was supported by the
		Hodgson et al (2014)	This work was supported by the
		Biswas et al (2014)	This work was supported by the
		Yoshida Klyori (2018)	This work was supported, in p
		Yoshida Klyori (2018)	This work was supported, in p
		Betts et al (2012)	Funding was provided by NEW
		Payne (2017)	This work was supported by a
		Payne et al (2017)	This work was supported by fu
0.72 £	377,196.48	Asthagiri Arunkumar (2019	The study was fundedby an M
0.72 £	61,020.00	McHanon M (2019)	The study was fundedby an M
		Gola (2018)	A.G. is funded by the Wellcom
		Gola (2018)	A.G. is funded by the Wellcom
		Gola (2018)	A.G. is funded by the Wellcom
		Munster (2017)	This work is published withthe
		McHanon M (2019)	The study was fundedby an M
			The study was fundedby an M
		McHanon M (2019)	The study was fundedby an M
0.72 £	2,222,191.44	Barnes et al (2012)	European Union (Framework
0.72 £	1,692,799.92	Kelly et al (2016)	Supported by a Medical Resea
		Munster (2017)	This work is published withthe
		Kelly et al (2016)	Supported by a Medical Resea
		Swadling (2016)	Supported by the Medical Res
		Swadling (2016)	Supported by the Medical Res
		Dicks et al (2015 - 2) Dicks et al (2012)	This work has been funded by This work has been funded by
		Mensah (2017)	This work has been funded by
		Payne (2017)	This work was supported by a
		Walker et al (2015)	Andrew S. Walker, José Loure
		Ewer et al (2013)	The study was funded by gran
			We thank the Jenner Institu
		O'Hara et al (2012)	Financial support. This work w

- - - - - 084113/Z/07/Z A91301 Adult Vaccine	NIHR (through Oxford Biomedical Resea NIHR Oxford Biomedical Research Centr NIHR Oxford Biomedical Research Centr	Barnes E	-	-
	NIHR Oxford Biomedical Research Centr NIHR Oxford Biomedical Research Centr		-	- -
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centr	-	-	-
A91301 Adult Vaccine	NIHR Oxford Biomedical Research Centr	-	-	-
A91301,Adult Vaccine	NIHR Oxford Biomedical Research Centr NIHR Oxford BRC	-	-	-
-	NIHR Oxford BRC	-	-	-
-	NIHR Oxford BRC	-	-	-
-	NIHR Oxford BRC	-		-
-	NIHR Oxford BRC	-	-	-
-	NIHR Oxford BRC	Kelly C	-	-
-	NIHR Oxford BRC	Klenerman P	-	-
_	NIHR Oxford BRC	Barnes E	_	-
91301 Adult Vaccine	NIHR Oxford BRC	-	_	_
58-5348-2-117F	Norman Borlaug Commemorative Resea	I -	_	_
-	Nuffield Department of Medicine	Reyes-Sandoval A	_	_
_	Nuffield Department of Medicine	Longley RJ		
	Nuffield Department of Medicine	Longley RJ		
_	Oak Foundation	-		
16/107/05		Payer Candaval A Datal All	-	-
16/107/05	ODA budget Ohyama Health Foundation	Reyes-Sandoval A, Patel AH	-	-
	Oxford Biomedical Research Centre	-	-	-
-		D-Ui CC	-	-
-	Oxford Mortin Institute	Rollier CS	-	-
-	Oxford Martin Institute Oxford Martin Institute	Spencer AJ Hill AVS	-	-
-			-	-
-	Oxford Martin School	Reyes-Sandoval A	-	-
-	Oxford Martin School	Hill A.V.S	-	-
-	Oxford Martin School	Reyes-Sandoval A	-	-
-	Oxford Martin School	-	-	-
-	Oxford Martin School	Barnes E	-	-
-	Oxford Martin School	Lambe T	-	-
-	Oxford Martin School	Spencer AJ	-	-
-	Oxford Martin School	Reyes-Sandoval A	-	-
-	Oxford Martin School	Barnes E	-	-
-	Oxford Martin School	Hill AVS	-	-
-	Oxford Martin School	-	-	-
-	Oxford Martin School	Spencer AJ	-	-
-	Oxford Martin School	Cottingham MG	-	-
-	Oxford Martin School	Cottingham MG	-	-
-	Oxford Martin Schools	Barnes E	-	-

Antrobus et al (2014) Cottingham et al (2012) Elias et al (2013) Swadling et al (2014) Ewer et al (2013) Biswas et al (2014) de Barra et al (2014) Kimani et al (2014)	The study was funded by gran This work was supported by the This work was supported by the Funding: Supported by the Mer. The study was funded by gran This work was supported by the study was funded by a gran This work was supported by the study was funded by a gran This work was supported by
Ogwang et al (2013) Sheehy et al (2012 - 2)	This work was performed by t This work was supported by th
Sheehy et al (2012)	This work was supported by
Hodgson et al (2014)	This work was supported by th
Longley et al (2015) Longley et al (2017) Stedman (2019) Lopez-Camacho (2018) Yoshida Klyori (2018) de Cassan et al (2011) Reyes-Sandoval et al (2010) Longley et al (2017) Salman et al (2017) Atcheson (2018) Atcheson (2018) Bauza et al (2014) Cottingham et al (2012) Kelly et al (2016) Lambe et al (2013) Longley et al (2015) Salman et al (2015)	This work was supported by the This work was supported by the Wellcome Tounding for manufacture and This work was supported by the This work was supported by the Supported by the Medical Res Trials Partnership (EDCTP) and This work was funded by the Ewe thank the Jenner Instituth This work has been funded by Funding for manufacture and This study was funded by the This report is independent res This work was supported, in p. S.C.d.C. is a Ph.D. student support of the We thank the Jenner Instituth Funding for manufacture and The work was funded by a We This work was funded by a We This work was funded by a We Supported by a Medical Resea Avl. was funded by a fellowsh This work has been funded by The work was funded by a We The work was funded by a fellowsh This work was funded by a We The work was funded by a fellowsh This work was funded by a We The work was funded by a We The work was funded by a fellowsh This work was funded by a We The We The The This work was funded by a We The We The This work was funded by a We The We The This work was funded by a We The We The This work was funded by a We The We The This work was funded by a We The This work was funded by a We The This work was
Swadling (2016) Bauza et al (2014) Antrobus et al (2014) Dicks et al (2015) Dicks et al (2015) Dicks et al (2012) Swadling et al (2014)	Supported by the Medical Res The work was funded by a We The study was funded by gran This work has been funded by This work has been funded by This work has been funded by Funding:Supported by the Mei

This work was supported by th

Sheehy et al (2011)

-	Oxford NHIRBRC	-	-	-			Kelly et al (2016)	Supported by a Medical Resea
-		Barnes E	-	-			Kelly et al (2016)	Supported by a Medical Resea
-	Oxford NIHR Biomedical Research Centre	-	-	-			Barnes et al (2012)	European Union (Framework
-	Oxford NIHR Biomedical Research Centre	Redchenko I	-	-			Capuccini et al (2016)	This work was supported by O
-	PATH Malaria Vaccine Initiative	-	-	-			Forbes et al (2012)	This work was funded by the \
-	PATH Malaria Vaccine Initiative	-	-	-			Hodgson et al (2014)	This work was supported by the
	PATH Malaria Vaccine Initiative	-	-	-			Rampling T (2018)	This work was funded primari
-	PATH Malaria Vaccine Initiative	-	-	-			Sheehy et al (2012)	This work was supported by
	PATH Malaria Vaccine Initiative	-	-	-			Biswas et al (2014)	This work was supported by the
	PATH Malaria Vaccine Initiative	-	-	-			Rampling et al (2016)	This work was supported by the
	PATH Malaria Vaccine Initiative (MVI)	-	-	-			Sheehy et al (2011)	This work was supported by the
	PATH MalariaVaccine Initiative	-	-	-			Hodgson et al (2015)	This work was supported by the
-	PATH MalariaVaccineInitiative	-	-	-			Sheehy et al (2012 - 2)	This work was supported by the
	PATH-MVI Malaria Vaccine Initiative	-	-	-			Draper et al (2011)	SB was funded by MalParTrain
	Public Health England	-	-	-			Ewer et al (2016)	Supported by the Wellcome T
-	ReiThera (formerly Okairos)	Nicosia A	-	-			Mensah et al (2016)	This study was supported by a
	Rhodes Trust	-	-	-			Longley et al (2015)	This work has been funded by
	Rhodes Trust	Longley RJ	-	-			Longley et al (2017)	Funding for manufacture and
	Rhodes Trust	Llewellyn D	-	-			Payne (2017)	This work was supported by a
	Science Foundation Ireland	-	-	-			Carey et al (2013)	This work wassupported by Er
NAP156	Science Foundation Ireland	-	-	-			Pearson et al (2015)	This study was funded by Ente
NAP170	Science Foundation Ireland	-	_	_			Pearson et al (2015)	This study was funded by Ente
	Southampton NIHR Wellcome Trust Clini	_	_	_			Sheehy et al (2012)	This work was supported by
	Southampton NIHR Wellcome Trust Clini		_	_			Rampling et al (2016)	This work was supported by the
AGL2017-82570-R	Spanish Ministry of Science	_		_			Utrilla-Trigo S (2020)	This work was supported by g
, , , , , , , , , , , , , , , , , , ,	·	Lopez-Gil E	_	_			Warimwe et al (2013)	This work was supported by a
AGL2011-22485	·	Brun AV	_	_			Warimwe et al (2013)	This work was supported by a
	·	Biswas S	_	_			Biswas et al (2014)	This work was supported by the
	Swedish International Development Coo		_	_			Afolabi et al (2016)	Trials Partnership (EDCTP) and
	Swedish International Development Coo		_	_			Mensah (2017)	This work was supported by a
	Swedish International Development Coo		_	_			Mensah et al (2016)	This study was supported by a
	Swedish International Development Coo		_	_			Tiono (2018)	This work was supported by a
	The Coalition for Epidemic Preparedness		_	_			Folegatti P.M.(2020)	UK Department of Health and
	·	Rollier CS	_	_				We thank the Jenner Institu
EU FP7	Transmolbloc	-	_				Goodman et al (2011)	This work was supported prim
EU FP7	Transmolbloc		-	-			Goodman et al (2011)	This work was supported prim
IU FF7	TRANSVAC	-	-	-			• •	
		-	-	-			de Cassan et al (2011) Bowyer G (2020)	S.C.d.C. is a Ph.D. student support of the Oxford clinical trial was s
	UK Department for International Develop		-	-			, , ,	This work was supported
Project 16/107/03	UK Department of Health and Social Con		-	-			Venkatraman N (2019) Stedman (2019)	
	UK Department of Health and Social Can		-	-			, ,	This study was funded by the
16/107/01 =D/D012756/1	UK Department of Health and Social Care		-	- £6,060,170	r	6 068 170 00	Folegatti P.M.(2020) Fedosyuk S (2019)	UK Department of Health and
EP/R013756/1	UK Engineeringand Physical Sciences Re	-	-	£6,968,179	£	0,308,173.00	Reyes-Sandoval (2010)	This work was supported by M Work in the Oxford malaria va
	UK Medical Research Council	-	<u> -</u>	-	-			
MC DC 10055	UK National Institute for Health Researc		- Anr 20 Can 21	- £2 174 047	£	2 174 047 00	Folegatti P.M.(2020)	UK Department of Health and
MC_PC_19055 GR000550	UK Research and Innovation UK Royal Society for Tropical Medicine a	Sarah Catherine Gilbert	Apr 20 - Sep 21	£2,174,847	Ĺ	2,1/4,84/.00	Folegatti P.M.(2020) Bliss (2020)	UK Research and Innovation, (
	, , ,	· ·	- Oat 16	- 0400.070	-	400 070 00	` '	This research project was sup
972216		Reyes-Sandoval A	Oct 16 - Sep 17	£498,870	£		Lopez-Camacho (2018)	This report is independent res
		Alexandar Douglas		£411,388.00	£	411,388.00		This COVID-19 Rapid Respons
		Sandy Douglas		£400,000.00	£	400,000.00		Working with Professor Sarah Gilbert
DDC /F /1 /0000000000		Graham Ogg		£246,000.00	£			This £246k award is to procur
BBS/E/I/00007037	UKRI Biotechnology and BiologicalScience	·	Apr 17 - Mar 20	£17,455,044			S Graham (2020)	UKRI Biotechnology and Biolo
BBS/E/I/00007039	UKRI Biotechnology and BiologicalScience	-	Apr 17 - Mar 20	£6,662,753	£		S Graham (2020)	UKRI Biotechnology and Biolo
BBS/E/I/00007031	UKRI Biotechnology and BiologicalScience	Philippa Beard	Apr 17 - Mar 20	£2,965,523	£	2,965,523.00	S Graham (2020)	UKRI Biotechnology and Biolo
BBS/E/I/00007034	UKRI Biotechnology and BiologicalScience	Simon Thomas Carpenter	Apr 17 - Mar 20	£2,728,186	£	2 720 100 00	S Graham (2020)	UKRI Biotechnology and Biolo

EP/R013756/1	UKRI Engineering and Physical Sciences	Tarit K Mukhopadhyay	Apr 18 - Sep 21	£6,968,179	£	6.968.179.00	S Graham (2020)	This study was supported by L
EP/S025243/1	UKRI Engineering and Physical Sciences		Nov 18 - May 20	£1,649,512	£		S Graham (2020)	andEPSRC Grant No. EP/S025
-	University of Oxford	-		,,-		,,-		This work was conducted with
MRF/TT2015/2150	University of Oxford	Coughlan L						This research project was sup
, ,	USAID	-						This work was supported by fu
-	Vaccine Research Center	-						This study was funded by a W
-	Vaccitech Ltd	-	-				Tuthill M. (2020)	European Union Seventh Fran
-	Wellcome Trust	-						The study was funded by gran
764	38 Wellcome Trust	-			-		• •	We thank the Jenner Institu
2061	94 Wellcome Trust	-			-			This work was supported by fu
-	Wellcome Trust	-			-			The Oxford clinical trial was s
-	Wellcome Trust	AVSH			-		Capone et al (2010)	This work was supported by th
-	Wellcome Trust	-			-		Capone et al (2010)	This work was supported by th
-	Wellcome Trust	Hill AVS			-		Capuccini et al (2017)	This work was supported by O
-	Wellcome Trust	-			-		Reyes-Sandoval (2010)	Work in the Oxford malaria va
-	Wellcome Trust	Reyes-Sandoval A			-		Reyes-Sandoval et al (2010	We thank the Jenner Institu
-	Wellcome Trust	-			-		Rollier C (2020)	This work was funded by a gra
-	Wellcome Trust	Hill A.V.S.			-		Rollier C (2020)	This work was funded by a gra
-	Wellcome Trust	-			-		Venkatraman N (2019)	This work was supported
084113/Z/07/Z	Wellcome Trust	-			-		Afolabi et al (2016)	Trials Partnership (EDCTP) and
084113/Z/07/Z	Wellcome Trust	-			-		Longley et al (2017)	Funding for manufacture and
084113/Z/07/Z	Wellcome Trust	-			-		Payne et al (2017)	This work was supported by fu
095540/Z/11/Z	Wellcome Trust	Hill AVS			-		Longley et al (2017)	Funding for manufacture and
095540/Z/11/Z	Wellcome Trust	Hill AVS			-		Salman et al (2017)	The work was funded by a W ϵ
097395/Z/11/Z	Wellcome Trust	Reyes-Sandoval A			-		Alves et al (2017)	The work was funded by a W€
097395/Z/11/Z	Wellcome Trust	Reyes-Sandoval A			-		Salman et al (2017)	The work was funded by a W€
097940/Z/11/Z	Wellcome Trust	Hodgson SH			-		Longley et al (2017)	Funding for manufacture and
106917/Z/15/Z	Wellcome Trust	Draper SJ			-		Payne et al (2017)	This work was supported by fu
204826/Z/16/Z	Wellcome Trust	Prof Matthew Freeman	07/09/2016	£3,000,000.00	£			This work was supported by N
106917/Z/15/Z	Wellcome Trust	Prof Simon Draper	01/04/2015	£1,901,424.00	£	1,901,424.00	Wang (2018)	This work has been supported
095540/Z/11/Z	Wellcome Trust	Hill A.V.S	10/05/2011	£1,372,456.00	£	1,372,456.00	Atcheson (2018)	The work was funded by a Wε
95540/Z/11/Z	Wellcome Trust	Prof Adrian Hill	10/05/2011	£1,372,456.00	£		•	This work has been funded by
97395/Z/11/Z	Wellcome Trust	Reyes-Sandoval A	12/12/2011	£1,081,461.00	£	1,081,461.00	Bauza et al (2014)	The work was funded by a We
201477/7/16/7	Wolleams Trust	Dr. Alexander Deugles	19/05/2016	C414 402 00	£	414 402 00	\\\ang (2019)	This work has been supported
201477/Z/16/Z	Wellcome Trust	Dr Alexander Douglas	18/05/2016	£414,492.00	Ĺ	414,492.00	Wang (2018)	This work has been supported
201477/Z/16/Z	Wellcome Trust	Douglas AD	18/05/2016	£414,492.00	£	414 492 00	Fedosyuk S (2019)	This work was supported by N
098635/B/12/Z	Wellcome Trust	Warimwe GM	21/06/2012	£253,778.00	£			This study was conducted witl
098635/B/12/Z	Wellcome Trust	Warimwe GM	21/06/2012	£253,778.00	£		, ,	This work was supported by a
094449/Z/10/Z	Wellcome Trust	Duncan CJ	31/08/2010	£218,216.00	£			This work was supported by
089455/Z/09/Z	Wellcome Trust	Douglas AD	29/05/2009	£217,651	£			This work was supported by fu
97395/Z/11/A	Wellcome Trust	Reyes-Sandoval A	01/08/2013	£203,200.00	£	203,200.00	. 3,	S on was supported by it
097940/Z/11/Z	Wellcome Trust	Hodgson SH	29/03/2012	£195,304.00	£	,	Kimani et al (2014)	This work was supported by
	38 Wellcome Trust	Prof Adrian Hill	16/09/2008	£84,023.00	£	84,023.00		The work was supported by a
098635/Z/12/Z	Wellcome Trust	Warimwe GM	21/06/2012	£74,551.00	£	74,551.00		This study was conducted witl
-	Wellcome Trust	-		27 .,552.50	-	,552.00	Barnes et al (2012)	European Union (Framework
							(- /	,

-	Wellcome Trust	-	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	Hill AVS	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	Hill AVS	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	Hill AVS	-	-
-	Wellcome Trust	Hill A.V.S	-	-
-	Wellcome Trust	Hill A.V.S.	-	-
-	Wellcome Trust	Gilbert SC	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	Hill AVS	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	Hill AVS	-	-
-	Wellcome Trust	Hill A.V.S	-	-
-	Wellcome Trust	Hill A.V.S	-	-
-	Wellcome Trust	Hill A.V.S.	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	Gavin Screaton	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	Hill AVS	-	-
-	Wellcome Trust	Hill A.V.S		
-	Wellcome Trust	Hill AVS	-	-
-	Wellcome Trust	-	-	-
-	Wellcome Trust	Kelly C	-	-
-	Wellcome Trust	Klenerman P	-	-
084113/Z/07/Z	Wellcome Trust	-	-	-
084113/Z/07/Z	Wellcome Trust	-	-	-
084113/Z/07/Z	Wellcome Trust	-	-	-
084113/Z/07/Z	Wellcome Trust	Hill AVS	-	_
084113/Z/07/Z	Wellcome Trust	-	-	-
084113/Z/07/Z	Wellcome Trust	_	-	_
084113/Z/07/Z	Wellcome Trust	-	-	-
084113/Z/07/Z	Wellcome Trust	Prof Adrian Hill	_	-
091663MA	Wellcome Trust	-	_	_
095540/Z/11/Z	Wellcome Trust	_	_	_
095540/Z/11/Z	Wellcome Trust	-	_	_
095540/Z/11/Z	Wellcome Trust	_	_	_
097940/Z/11/Z	Wellcome Trust	Hodgson SH	_	_
097940/Z/11/Z	Wellcome Trust	Hodgson SH	_	_
	Wellcome Trust	-	-	-
097940/Z/11/Z)		Hodgson SH	-	-
099897/Z/12/A	Wellcome Trust	-	-	-
45488/Z/05	Wellcome Trust	Hill AVS	-	-
45488/Z/05	Wellcome Trust	Hill AVS	-	-
45488/Z/05	Wellcome Trust	Hill AVS	-	-
45488/Z/05	Wellcome Trust	Hill AVS	-	-
45488/Z/05	Wellcome Trust	Hill AVS	-	-
RTEI0	Wellcome Trust	Duncan CJ	-	-
WT076943MA	Wellcome Trust	McShane H	-	-
WT098051	Wellcome Trust	-	-	-
WT098635	Wellcome Trust	Warimwe GM	-	-

Bliss (2018)	This study was funded by the
Boyd et al (2013)	The Biotechnology and Biolog
Capuccini et al (2016)	This work was supported by O
Colloca et al (2012)	This work was supported in pa
Cottingham et al (2012)	This work was supported by th
de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supp
Dicks et al (2012)	This work has been funded by
Dicks et al (2015 - 2)	This work has been funded by
Draper et al (2010)	This work was funded by the \
Draper et al (2011)	SB was funded by MalParTrain
Draper et al (2011)	SB was funded by MalParTrain
Ewer et al (2013)	The study was funded by gran
Ewer et al (2013)	The study was funded by gran
Forbes et al (2012)	This work was funded by the \
Forbes et al (2012)	This work was funded by the \
Gola (2018)	A.G. is funded by the Wellcom
Gola (2018)	A.G. is funded by the Wellcom
Goodman et al (2011)	This work was supported prim
Halbroth (2018)	BRH received funding from th
Kelly et al (2016)	Supported by a Medical Resea
Lopez-Camacho (2018)	This report is independent res
Tapia et al (2016)	This study was funded by a W
Tapia et al (2016)	This study was funded by a W
Walker et al (2015)	Andrew S. Walker, José Loure
Halbroth (2018)	BRH received funding from th
Colloca et al (2012)	This work was supported in pa
Ewer et al (2016)	Supported by the Wellcome T
Swadling (2016)	Supported by the Medical Res
Swadling (2016)	Supported by the Medical Res
de Barra et al (2014)	The study was funded by a gra
Elias et al (2013)	This work was supported by th
Hodgson et al (2014)	This work was supported by th
Hodgson et al (2015)	This work was supported by th
Kimani et al (2014)	This work was supported by
Sheehy et al (2011)	This work was supported by th
Sheehy et al (2012 - 2)	This work was supported by th
Sheehy et al (2012)	This work was supported by
Colston et al (2016)	This work was supported by V
Dicks et al (2015)	This work has been funded by
Longley et al (2015)	This work has been funded by
Spencer et al (2014)	This work has been funded by
de Barra et al (2014)	The study was funded by a gra
Hodgson et al (2015)	This work was supported by th
Biswas et al (2014)	This work was supported by th
Colston et al (2016)	This work was supported by V
de Barra et al (2014)	The study was funded by a gra
Hodgson et al (2015)	This work was supported by th
Sheehy et al (2011)	This work was supported by the
Sheehy et al (2012 - 2)	This work was supported by the
Sheehy et al (2012) Sheehy et al (2012 - 2)	This work was supported by This work was supported by the
Betts et al (2012)	Funding was provided by NEW
Bauza et al (2014)	The work was funded by a We
• •	This work was runded by a We
Warimwe et al (2016)	iiiis work was conducted WITF

9739	5 Wellcome Trust	Reyes-Sandoval A	-	-	-		Betts et al (2012)	Funding was provided by NEW
-	Wellcome Trust	Hill AVS	-	-	-		Dicks et al (2012)	This work has been funded by
-	Wellcome Trust	-	-	-	-		O'Hara et al (2012)	Financial support. This work w
084113/Z/07/Z	Wellcome Trust	-	-	-	-		Ogwang et al (2013)	This work was performed by t
WT 098051	Wellcome Trust	Otto TD	-	-	-		Payne (2017)	This work was supported by a
203077/Z/16/Z	Wellcome Trust	Prof Philip Bejon	30/06/2016	£26,595,243.00	£	26,595,243.00	Stedman (2019)	This study was funded by the
084113/Z/07/Z	Wellcome Trust	Prof Adrian Hill	07/11/2007	£3,400,000.00	£	3,400,000.00	de Cassan et al (2011)	S.C.d.C. is a Ph.D. student supp
							, ,	
084113/Z/07/Z	Wellcome Trust	Prof Adrian Hill	07/11/2007	£3,400,000.00	£	3,400,000.00	Payne (2017)	This work was supported by a
106325/Z/14/A	Wellcome Trust	A.V.S Hill	19/12/2014	£2,100,000.00	£	2,100,000.00	Venkatraman N (2019)	This work was supported
106917/Z/15/Z	Wellcome Trust	Draper SJ	01/04/2015	£1,901,424.00	£	1,901,424.00	Payne (2017)	This work was supported by a
097395/Z/11/Z	Wellcome Trust	Reyes-Sandoval A	12/12/2011	£1,081,461.00	£	1,081,461.00	Atcheson (2018)	The work was funded by a Wε
108734/Z/15/Z	Wellcome Trust	Rawlinson TA	24/06/2015	£271,399.00	£	271,399.00	Payne (2017)	This work was supported by a
-	Wellcome Trust	A.V.S Hill	-	-			Bowyer (2018)	The clinical trial was supporte
-	Wellcome Trust	Gola A	-	-			Gola (2018)	A.G. is funded by the Wellcom
-	Wellcome Trust	-	-	-			Mensah (2017)	This work was supported by a
-	Wellcome Trust Clinical Research Facili	it -	-	-			Barnes et al (2012)	European Union (Framework '